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Abbreviations  
 
Abbreviation Full name 
Arf ADP ribosylation factor  
Arl Arf-like  
Arp actin-related protein 
ATP adenosine triphosphate  
BCR breakpoint cluster region protein 
BSA bovine serum albumin  
Cdc42 cell division cycle-42 
CDK1 cyclin-dependent kinase 1  
DAG diacylglycerol  
DAPI 4′,6-diamidino-2-phenylindole 
DH Dbl homology  
DHR Dock homology region  
DMEM Dulbecco's modified Eagle medium 
DMSO dimethyl sulfoxide 
DTT dithiothreitol  
EC50 half maximal effective concentration  
Ect2 epithelial cell transforming sequence 2  
EGF epidermal growth factor  
EGTA ethylene glycol tetraacetic acid 
EMEM Eagle's minimum essential medium 
Erk extracellular signal-regulated kinase  
FBS fetal bovine serum 
GAP GTPase activating protein 
GDF GDI displacement factors  
GDI guanine nucleotide dissociation inhibitor  
GDP guanosine diphosphate  
GEF guanine nucleotide exchange factor 
Grb2 growth factor receptor-bound protein 2  
GTP guanosine triphosphate  
GTPase guanosine triphosphatases  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HTS high-throughput screening 
IC50 half maximal inhibitory concentration 
IF immunofluorescence  
IL-6 (or IL6) interleukin-6  
IL6R interleukin-6 receptor 
IPTG isopropyl β-D-1-thiogalactopyranoside  
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JNK c-Jun NH2-terminal kinase 
MAP mitogen-activated protein  
MEK mitogen-activated protein kinase/Erk kinase 
MgcRacGAP Male Germ Cell RacGAP  
MINC1 MgcRacGAP Inhibitor Compound 1 
Miro mitochondrial Rho  
MKLP1 mitotic kinesin-like protein 1 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NF-1 neurofibromin  
PAINS pan-assay interference compounds  
PAK p21-activated kinase  
PAR partitioning defective homolog  
PBD p21 binding domain 
PBS phosphate-buffered saline  
PCR polymerase chain reaction 
PDEδ delta subunit of retinal rod phosphodiesterase 
PH pleckstrin homology  
PI3K phosphatidylinositol-3 kinase  
PKB protein kinase B  
PKN protein kinase N  
Plk1 polo-like kinase 1  
PMSF phenylmethylsulfonyl fluoride 
PRC1 protein regulator of cytokinesis  
PTEN phosphatase and tensin homolog  
PVDF polyvinylidene fluoride  
QRET quenching resonance energy transfer  
Rab Ras-related proteins in brain  
Rac Ras-related C3 botulinum toxin substrate 
Ral Ras-like  
Ran Ras-like nuclear  
Rap Ras proximal  
Ras rat sarcoma  
RBD Ras binding domain 
REM Ras exchange motif 
Rho Ras homologous  
RNA ribonucleic acid 
RNAi RNA interference 
ROCK Rho-associated protein kinase  
ROS reactive oxygen species  
RPMI Roswell Park Memorial Institute 
Sar secretion-associated and Ras-related  
SAR structure-activity relationship  
SD standard deviation 
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SH Scr homology 
siRNA small interference RNA  
Sos son of sevenless  
STAT signal transducer and activator of transcription  
Tiam1 T-lymphoma invasion and metastasis-inducing protein 1  
TRL time-resolved luminescence  
v/v volume/volume 
w/v weight/volume 
WASP Wiskott-Aldrich syndrome protein  
WAVE WASP family verprolin-homologous  
WB western blot 
 
 
Amino Acid 3-Letter 1-Letter 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Abstract 
 
Small guanosine triphosphatases (GTPases) are a family of low molecular 
weight guanosine diphosphate (GDP)-/guanosine triphosphate (GTP)-
binding proteins that act as “molecular switches”, regulating key cellular 
processes, such as cell proliferation and differentiation. The activity of 
small GTPases is controlled by guanine nucleotide exchange factors 
(GEFs), which facilitate nucleotide exchange from GDP to GTP, and 
GTPase activating proteins (GAPs), which stimulate intrinsic GTP 
hydrolysis of the GTPase. Complex, yet unresolved, mechanisms maintain 
the precise spatiotemporal regulation of these proteins, which is essential 
for accurate cellular signaling. Accordingly, aberrant function of small 
GTPases is associated with a large number of human diseases, such as 
cancer, neurodegenerative diseases and inflammatory disorders. The 
availability of small molecule modulators of GTPase activity would be 
highly valuable to improve the understanding of small GTPases of the Ras 
superfamily and their regulators. However, very few probes of this kind 
currently exist. To address this gap, I have focused on discovering 
different small GTPase-modulating probes through different screening 
approaches.   
 
MgcRacGAP is a GAP protein for Rho family small G-proteins and a key 
regulator of cytokinesis. After almost two decades of research, the 
detailed functional role, its relevant target GTPase and its GAP activity in 
cytokinesis are not yet fully resolved. Furthermore, like many other 
regulators of GTPase activity, its overexpression has been linked to 
different malignant properties, such as epithelial-to-mesenchymal 
transition, cell polarity and (invasive) migration, as well as correlated to a 
poor clinical prognosis in many types of cancers. To be able to investigate 
the biological role of MgcRacGAP, we first addressed the lack of chemical 
tools to probe its function by developing a high throughput screening 
strategy to identify compounds inhibiting its GAP function. The discovery 
of MgcRacGAP Inhibitor Compound 1 (MINC1), a selective MgcRacGAP-
Rac1 inhibitor, represents the first described selective small molecule 
inhibitor of a Rho GTPase activating protein and shows that development 
of inhibitors of small GTPase activating proteins is possible. We utilized 
MINC1 to study the function of MgcRacGAP in cell division as well as the 
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role in the events that regulate signal transducer and activator of 
transcription 3 (STAT3) signaling. Notably, we showed that MINC1-
mediated inhibition of MgcRacGAP caused impaired mitotic spindle 
formation during the metaphase, which suggests that the GAP activity of 
MgcRacGAP plays an important role in mitosis. To address the role of 
MgcRacGAP in the events that regulate STAT3 phosphorylation and 
subsequent nuclear translocation, we used both MINC1 treatment and 
small interference RNA (siRNA)-mediated gene silencing of MgcRacGAP. 
With these complementary techniques we showed that inhibition of 
MgcRacGAP triggers STAT3 phosphorylation caused by a Rac1-PAR3-IL6-
IL6R-JAK2 mediated autocrine/paracrine mechanism. 
 
Due to their key role in different essential cellular processes, non-specific 
inhibition of GTPases or their regulators is expected to result in significant 
risk of side effects. Compounds that interfere with specific protein-protein 
interactions are expected to circumvent this problem, yet most current 
screening methods fail to detect these. To address this, we have 
developed a protein-protein interaction inhibitor screening strategy for the 
oncoprotein Ras and identified ten compounds that inhibited GTP 
hydrolysis in a concentration dependent manner. Four of these 
compounds could not be detected with the established method. Of the 
three compounds that showed efficacy in Ras signaling dependent cell 
lines, one compound had a direct effect on the activation status of Ras.  
 
In summary, this thesis describes i) the discovery of the first RhoGAP 
inhibitor named MINC1, ii) the application of MINC1 to elucidate the role 
of MgcRacGAP in the activation and nuclear translocation events of STAT3 
and iii) the development and exploration of a new screening strategy to 
discover Ras protein-protein inhibitors.  
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1. Introduction 
 
With the advances in science in the last fifty years, and particularly in the 
field of molecular biology with the discovery of tools to analyze and 
manipulate genes and proteins, there has been a growing understanding 
of the underlying biology that drive diseases. The identification of so-
called oncogenes and subsequent increasing understanding of their 
function at molecular level, has associated various members of the 
GTPase and kinase protein families with cancer and many other diseases, 
such as neurodegenerative diseases and inflammatory disorders. As a 
result, drug development has become more biology-driven, rather than 
based on serendipity. Kinases, with approximately 30 approved drugs for 
cancer treatment and more in clinical trails, have been successfully 
targeted in cancer drug discovery. However, less than a few clinically 
relevant GTPase targeting drugs have made it to the market to date. 
There are several reasons for this discrepancy. Despite both being 
nucleotide-binding proteins, small GTPases show a higher affinity for 
guanine nucleotides than kinases do for adenosine nucleotides, making it 
more difficult to compete against with a small molecule inhibitor. In 
contrast to kinases, there are no other obvious small molecule-binding 
pockets on small GTPases besides the nucleotide-binding pocket. Kinase 
inhibitor discovery has been enabled by high enzymatic activity of 
kinases, as it was it easier to develop sensitive biochemical assay that 
needed only low amount of protein. Last, while both small G-proteins and 
kinases tend to serve as nodes in signaling transduction, other domains 
within the protein itself regulate kinases, whereas up- and downstream 
regulatory proteins as well as scaffolding proteins direct GTPase activity 
and thereby determine the role of a GTPase in a wide range of different 
signaling pathways. As a result, targeting GTPases is expected to result in 
very broad unspecific inhibitory effect, leading to severe side effects. On 
the other hand, targeting GTPase-regulatory proteins is expected to result 
in specific modulation of select GTPase signaling pathways. In this thesis, 
my aim was to elucidate the function of GTPase-regulating proteins such 
as MgcRacGAP using small molecule modulators identified through novel 
screening assays.   
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2. Literature review 
The Ras superfamily of small guanosine triphosphatases (GTPases) 
comprises over 150 members in humans that all share a common 
biochemical characteristic: Cycling between a guanosine triphosphate 
(GTP)-bound state and a guanosine diphosphate (GDP)-bound state, 
small GTPases act as molecular switches in a variety of cellular processes 
(Figure 1)2,3,5. Besides regulating normal physiological processes, small 
GTPases and their regulators have been shown to contribute to malignant 
tumor characteristics such as invasiveness, metastasis, inflammation and 
relapse-causing regeneration4,6-9. Because of this biological and 
therapeutic potential, small GTPases have been considered targets from a 
drug discovery perspective ever since their discovery. In this review, I will 
first introduce the small GTPases and their regulators, focusing mainly on 
Ras and Rho family proteins. Furthermore, I will discuss the drug 
discovery efforts in the field of small GTPases. And last, I will go in 
greater detail on the function of Male Germ Cell RacGAP (MgcRacGAP, 
gene name RACGAP1), both in physiological and pathological processes 
and why there is a need for MgcRacGAP inhibitors.  
 
Figure 1 The small GTPase cycle. Most small GTPases cycle between what is commonly 
considered an inactive GDP-bound and an active GTP-bound form. In vivo, their intrinsic activity is 
regulated by guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs) and 
guanine–nucleotide-dissociation inhibitors (GDIs). Active GTPases interact with effector proteins to 
mediate a response. GDP, guanosine diphosphate; GTP, guanosine triphosphate Pi, inorganic 
phosphate. 
??????
?? ?
??
??????
???
???
??????
??????
???
Effector
???
????????
???
GDI
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?????????????????????????????????????????
Highly conserved from lower eukaryotes to mammals, the Ras 
superfamily of small GTPases is divided into five major families based on 
their genomic sequence and functional similarities: Ras, Rho, Rab, Arf and 
Ran (Figure 2A)3,10. All small GTPase proteins have a conserved ~20 kDa 
catalytic domain, built of a six-stranded β-sheet surrounded by five α-
helices, which includes the five conserved motifs (G1-G5) that recognize 
the β-phosphate and the magnesium ion or the guanine base (Figure 
2B)2,11,12. Two highly flexible segments within this domain, switch I and 
II, facilitate the conformation change that distinguish the GTP- and GDP-
bound forms13. Switch I region corresponds with the conserved G2 motif 
and is part of the so-called effector binding domain, whereas switch II 
region comprises the G3 and the c-terminal adjacent α2 helix14. The 
distinct conformational change resulting from the substitution of GDP by 
GTP causes the GTP-bound GTPase proteins to bind with great affinity to 
effector proteins, as was shown for Ras and Raf13,15.  
 
In addition to the domains common for all small GTPases, there are 
structural features that are restricted to one or a few subfamilies (Figure 
2B). Arf proteins have an amino-terminal extension, whereas Ran 
proteins contain a carboxy-terminal extension. In both cases, substitution 
of GDP by GTP causes a large conformational change in switch I, 
Figure 2 (next page) The mammalian Ras GTPase superfamily and GTPase functional 
domains. A) The Ras superfamily of small GTPases is divided into five subfamilies: Ras, Rho, 
Ran, Rab and Arf. Subfamilies, grouped according to structural similarity criteria in smaller 
highlighted areas, share the same color throughout the figure. The GTPase proteins studied in 
this thesis are depicted in increased font. B) Schematic representation of the protein domains 
of Ras superfamily members. The core G-domain, corresponding to Ras residues 4–166, 
contains the nucleotide binding domains (G1-5, gradient black), the effector binding domain 
(residues 32-40, pink), and the switch regions (S1 and SII). Ras, Rho and Rab proteins 
terminate in a hypervariable region (HV) that is essential for membrane binding. Arf and Ran 
family GTPases contain amino-terminal (N) and carboxyl-terminal extension (C), respectively. 
The Rho family specific domain (Rho insert, yellow triangle) is inserted between Ras residues 
122 and 123. (Image adapted from Vega and Ridley1, Wennerberg, Rossman and Der3 and Vigil 
et al.4) 
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repositioning the terminal extension and enabling regulator/effector 
interactions16-18. A so-called Rho-specific insert domain of 9-12 residues 
distinguishes Rho proteins from the others19. Ras, Rho and Rab small 
GTPases have carboxy-terminal hypervariable sequences, which terminate 
in case of most Ras and Rho GTPases with a CAAX motif and for Rab with 
cysteine-containing motifs (CC, CXC, CCX, CCXX, or CCXXX; C=cysteine, 
A=aliphatic, X=any amino acid). These motifs enable post-translational 
modification with lipophilic groups by prenylation (farnesylation or 
geranylgeranylation) or palmitoylation, which enhances the small GTPase 
interaction with different cellular membranes (reviewed in [20,21]). It is 
through these post-translational modifications that small GTPase proteins 
gain their characteristic subcellular membrane compartment localization 
and can fulfill their physiological function by interacting with membrane-
associated regulator and effector proteins. 
 
 
?????? ??????????????????????????? ??????????????
In order to successfully localize to the membrane small GTPase proteins 
need to go through a series of posttranslational modifications after 
synthesis20. In this maturation process, lipophilic groups are attached to 
the GTPase protein to provide an anchor for membrane association 
(Figure 2B). To illustrate, Ras proteins first receive by prenylation a 15-
carbon atom farnesyl or the 20-carbon atom geranylgeranyl group on the 
cysteine residue in the CAAX-motif at the C-terminal end in the 
cytoplasm22,23. Thereafter, in the endoplasmic reticulum24 the last three 
amino acids, the AAX sequence, are removed by proteolytic cleavage25, 
and subsequently a carboxymethyl group is introduced on the C-terminal 
cysteine residue26. This first series of posttranslational modifications 
provides the first signal and, together with the second signal coming from 
the polybasic positively-charged lysine residues upstream of the C-
terminus in K-Ras 4B, it enables membrane association for this Ras 
isoform27. For K-Ras 4A, H- and N-Ras, the second signal required for 
correct membrane association is provided by a 16-carbon atom palmitoyl 
fatty acid moiety that is added in the Golgi complex to an upstream C-
terminal cysteine residue24,27.  
 
Generally, the proteins of the Ras superfamily are grouped on the basis of 
the abovementioned sequence homologies, however these distinct 
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structural features also determine subcellular localization and thereby 
their specific functions in the cell. Where Rab and Arf GTPases appear to 
be the regulating proteins in the stepwise process of vesicular transport 
between donor and acceptor membrane-bound compartments, Ras and 
Rho GTPases function as signaling hubs in a myriad of different pathways, 
conveying signals to different effector pathways depending on the 
signaling complex formed. 
 
 
???????????????????????????????????????????
The Ras oncoproteins were discovered on the basis of the homology to 
the rat sarcoma virus genes28,29, and are the founding members of the 
Ras superfamily of small GTPases that were discovered in later studies. 
Early studies on the viral HRAS and KRAS oncogenes showed that these 
genes encode for 21 kDa proteins30, which can also be found in the 
normal genomic DNA of, and expressed by vertebrate cells31-33. Both the 
viral encoded, as well as the endogenously expressed proteins were 
demonstrated to be membrane-associated34,35, and able to bind guanine 
nucleotides34,36. The preferential binding to GTP of viral Ras isoforms was 
shown to enable Ras overexpression-induced cellular transformation of 
the host cell36-38, and that the guanine nucleotide-binding activity is 
common to the family members and regulate, among other things, cell 
proliferation and survival. Their aberrant function was discovered when 
the transforming genes in human cancer cells were identified as mutated 
HRAS and KRAS39-41. To date, the Ras family contains 36 members in 
mammals3,42. In addition to the Ras proteins, it contains two more major 
groups; Ras-like (Ral) proteins, which regulate vesicle sorting, cell 
morphology as well as proliferation43, and Ras proximal (Rap) proteins, 
which are regulators of integrin activation and cell motility44, as well as 
some less studied other groups (Figure 2A).  
 
In their mature form, Ras proteins are activated in response to a large 
variety of extracellular signals, including many different receptor tyrosine 
kinases, various G-protein-linked receptors, as well as intracellular second 
messenger signals, such as calcium45. While activated, Ras can interact 
with numerous effector proteins to initiate downstream signaling, of which 
best-characterized is the Raf kinase46-49, leading to activation of the 
mitogen-activated protein (MAP, also known as Erk, extracellular signal-
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regulated kinase) kinase pathway50,51. Furthermore, Ras-GTP interacts 
with lipid kinases, like the phosphatidylinositol-3 kinase (PI3K)52-54, which 
results in the increase of phosphatidylinositol-3,4,5-trisphosphate and 
subsequent phosphorylation of protein kinase B (PKB, also known as Akt) 
by 3-phosphoinositide-dependent protein kinases55,56. Additionally, Ras 
also interacts with regulatory proteins of other GTPase proteins. For 
instance, signaling from Ras GTPase family member Ral57,58, and Rho 
GTPase family member Rac59,60, is initiated through Ras effector proteins 
(Figure 3). Interestingly, whereas Ras binds to and signals through p110α 
subunit of PI3K53,54, Rho GTPase family members Ras-related C3 
botulinum toxin substrate (Rac) and cell division cycle-42 (Cdc42) 
regulate PI3K through the other regulatory subunit61,62.  
 
The best-studied Rho GTPases are the members of the Rho, Rac and 
Cdc42 subfamilies, which primarily have been studied in their function as 
regulators of cytoskeletal reorganization in response to extracellular 
signals. RhoA-C enable the formation of stress fibers and focal adhesion 
assembly by actin polymerization, whereas Rac1, Rac3 and RhoG are 
responsible for lamellipodium formation as well as membrane ruffling and 
the members of the Cdc42 subgroup direct filopodia formation through 
actin polymerization63-67. In addition to cytoskeletal reorganization, Rho 
GTPase proteins have been implemented in numerous other cellular 
responses, such as the involvement of Rho in smooth muscle 
contraction68, Rac in the generation of reactive oxygen species (ROS)69-72, 
and Cdc42 in the endo- and exocytosis of vesicles73-76 
 
Like Ras, active Rho GTPases promote the activation of numerous 
effectors of which the major pathways have been included in Figure 3. 
Some of these effectors are GTPase specific; Rho-associated protein 
kinases (ROCKs)77-80 and protein kinase N (PKN)81,82 are Rho downstream 
effectors that promote formation of stress fibers and focal adhesions, Rac-
specific ROS-generating NADPH oxidase69-72, as well as WASP family 
verprolin-homologous (WAVE)83, and Wiskott-Aldrich syndrome protein 
(WASP) or N-WASP as Cdc42-specfic targets84-86. While the interaction of 
Rac1 and Cdc42 is specific with WAVE and WASP, respectively, both 
effectors interact directly with Actin-related protein-2/3 (Arp2/3) complex 
to promote actin polymerization. Other shared downstream pathways are 
the c-Jun NH2-terminal kinase (JNK) and p38 MAP kinase cascade as well 
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as NF-kB, by which Rho GTPases regulate gene transcription87-90. 
Furthermore, many other effectors are directly shared, such as p21-
activated kinase (PAK)-family kinases for Rac and Cdc4291-93  
 
 
Figure 3 Snapshot of the Ras/ Rho GTPase signaling networks. Extracellular stimuli act 
through cell surface receptors, such as G-protein-coupled receptors (GPCRs), receptor tyrosine 
kinases (RTKs) as well as integrins, to recruit guanine nucleotide exchange factors (GEF), which in 
turn activate GTPases. Once activated, GTPase proteins can stimulate a wide range of different 
downstream pathways. Note that the system is a highly integrated network, with several feed-
forward and feedback loops at several layers. For example, EGF receptor-mediated activation of 
promiscuous Ras/Rho GEF Sos initiates Ras signaling94. Activated Ras initiates several signaling 
cascades, among which two best characterized are the Raf-Mek-Erk pathway46-49, leading into 
gene expression that mediates cell cycle progression, and PI3K-Akt pathway48,49, promoting cell 
survival. Furthermore, Ras signaling branching to the Ral and Rho GTPase signaling network by 
activating several GEFs. Rho GTPase activation results in cytoskeletal rearrangements, enabling 
cell motility as well as cytokinesis. For example, Rac1 and Cdc42 stimulate actin polymerization 
through Arp2/3 complex. The Arp2/3 complex also acts as a scaffold protein that binds Tiam1, 
which in turn will activate the Rac1-WAVE pathway and increased activation of the Arp2/3 
complex95. Arp2/3, actin-related protein 2/3; Cdc42, cell division cycle-42; Erk, extracellular 
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(Figure 3 continue) signal-regulated kinase; JNK, Jun N-terminal kinase; Mek, mitogen-activated 
protein kinase/Erk kinase; mTor, mammalian target of rapamycin; NF-κB, nuclear factor-κB; PAK, 
p21-activated kinase; PI3K, phosphoinositide 3-kinase; PLD, phospholipase D; Rac, Ras-related C3 
botulinum toxin substrate; Ral, Ras-like protein; RalBP1, Ral-binding protein-1; ROCK, Rho kinase; 
Sos, son of sevenless; TIAM1, T-cell lymphoma invasion and metastasis-1; WAVE, WASP family 
verprolin-homologous; WASP, Wiskott-Aldrich syndrome protein. (Figure is based on Berndt, 
Hamilton and Sebti96, Repasky, Chenette and Der97, Schwartz98, Karnoub and Weinberg99 as well 
as Biro, Munoz and Weninger100.)  
 
There is notable cross-talk between the Ras and Rho GTPase subfamilies, 
a good example being the direct regulation of PI3K by Rac and Cdc4261,62, 
as well as the indirect regulation via RhoA-mediated ROCK activation and 
subsequent stimulation of phosphatase and tensin homolog (PTEN)101,102, 
a direct suppressor of PI3K activity103,104. In turn, PI3K can activate Rho 
GTPase regulatory proteins105,106, mediating the activation of PAK family 
kinases by Rho GTPases and subsequent phosphorylation of MAP kinase 
Raf107,108.  
 
The ADP ribosylation factor (Arf) and Ras-related proteins in brain (Rab) 
families direct intracellular vesicular trafficking42,109-112. With over 30 and 
approximately 70 family members in the Arf and Rab subfamilies, 
respectively42, they comprise more than half of the small GTPase 
proteins. The minimal amount of Rab proteins essential for a viable 
eukaryotic cell is eleven113. The substantial number of different proteins is 
the result of expansion by gene duplication that led to segregation by 
specialization of function in higher eukaryotes114. Localization and 
function in different transport processes is dependent on the C-terminal 
sequences (different cysteine-containing motifs, see Figure 2B) and 
post-translational modifications. Substitution of different prenyl anchors 
on Rab GTPases is followed by incorrect localization to their characteristic 
organelle membrane115.  
 
Like Rab proteins, Arf proteins have distinct cellular localization116. This 
distinct localization is important for downstream signaling, as in vitro 
binding assays have shown that many Arf effector proteins can interact 
with more than one Arf protein117-119. For example, it has been suggested 
that the role of Arf6 at plasma membrane is similar to the role of Arf1 at 
the Golgi, however by spatial separation each protein fulfills unique 
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functions. Where Arf6 regulates endocytic membrane trafficking and actin 
remodeling, Arf1 controls the formation of coat protein I-coated vesicles, 
recruitment of clathrin through adapter protein complexes as well as the 
assembly of other organelle structures111,112. Arf proteins, as well as Arf 
subfamily members Arf-like (Arl) and more distantly related secretion-
associated and Ras-related (Sar) proteins, regulate vesicle budding from 
donor compartments, while Rab subfamily member proteins regulate the 
subsequent steps in the endo- or exocytotic vesicles trafficking pathway, 
like the coupling of vesicles to motor proteins, regulating vesicle motility 
as well as the formation of large protein complexes required for tethering 
and subsequent docking and fusion of the vesicles with the acceptor 
compartments (reviewed in [109,120]). 
 
The single family-member Ras-like nuclear (Ran) protein42, presumably 
the most abundant small GTPase in the cell121, has an essential role in the 
nucleocytoplasmic transport of macromolecules, such as ribonucleic acid 
(RNA) and proteins122,123. In interphase cells, GTP-bound Ran is highly 
compartmentalized in the nucleus, whereas GDP-bound Ran resides in the 
cytoplasm124,125. This spatial gradient of the GTP-bound Ran facilitates the 
directionality of nuclear import and export126,127. To illustrate, in the 
cytoplasm, GDP-bound Ran binds to importins and their cargo and 
subsequently translocates to the nucleus. In the nucleus, Ran becomes 
GTP-bound by nucleotide exchange and as a result the complex 
dissociates. Exportins, on the other hand, need GTP-bound Ran to 
transport their cargo and will release this upon GTP hydrolysis in the 
cytoplasm. Furthermore, in addition to its function in interphase cells, Ran 
GDP/GTP cycling was demonstrated to be involved in mitotic spindle 
formation128-131, as well as the induction of the nuclear envelope 
assembly132,133.  
 
 
 
?????????????????????????????????
 
Most small GTPases have an intrinsic ability to exchange the bound 
nucleotide and to hydrolyze bound GTP, yet, in vivo, this intrinsic ability is 
accelerated by guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs), respectively45,134. Being able to modulate 
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GTPase activity, GEFs and GAPs are controlling GTPase-mediated 
signaling. So-called adaptor and scaffold proteins assist by attracting the 
proteins needed in the signaling pathway, localizing GTPase, GEF and GAP 
proteins to specific places at the cellular membrane and thereby 
determine which downstream pathways are activated. To illustrate, the 
activation of the RasGEF son of sevenless (Sos)135,136 through the 
epidermal growth factor (EGF) receptor tyrosine kinase mediates Ras 
signaling94 (Figure 3). Growth factor receptor-bound protein 2 (Grb2), an 
adaptor protein that is recruited to tyrosine-phosphorylated receptors, 
facilitates Ras activation by binding to the EGF receptor with its Src 
homology (SH) 2 domain, and Sos protein with its SH3 domain137. In 
turn, Ras-GTP can bind RhoGEF T-lymphoma invasion and metastasis-
inducing protein 1 (Tiam1)138, which results in the activation of Rac 
signaling59,139. However, in addition to a RasGEF domain, Sos contains 
another GEF domain that is Rac1 specific and, in complex with the 
scaffold proteins Abi1–Eps8 and PI3K, enables Rac signaling140,141. The 
adaptor protein Grb2 and scaffold protein Abi1 interact with the same 
region of Sos, thereby facilitating the differential regulation of Ras versus 
Rac activity of Sos140. While Sos is unique, having two GEF domains, 
similar complex dependent pathways have been described for other GEFs. 
For example, the interaction of the RhoGEF Tiam1 / Rac1 complex with 
insulin receptor substrate p53/p58 leads to actin polymerization142, 
whereas the interaction of this complex with spinophilin activates p70 S6 
kinase143. 
 
 
??????????????????????????????????????????
Since GEFs are required for the rapid exchange of GDP for GTP, the 
modulation of their catalytic activity is considered the most common 
mechanism to alter GTPase-mediated signaling, thereby linking activated 
plasma membrane receptors to downstream GTPases as well as mediating 
the signaling from one GTPase pathway to the other (Figure 3). The pre-
dominantly membrane-associated GEF proteins catalyze the exchange of 
GDP by causing a conformational change of the small GTPase that lowers 
the affinity for the nucleotide as well as stabilize the nucleotide-free 
reaction intermediate144. The mechanism by which GEF proteins catalyze 
the nucleotide exchange is depending on the 20-30 kDa family-specific 
catalytic domain. Although the GEFs are structurally unrelated, the 
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multistep GEF-dependent nucleotide exchange follows a common principle 
(Figure 4A), which was first shown with Ras/Sos145 and Arf/Sec7146.  
 
GEF-GTPase binding causes a conformational change of the small GTPase 
protein structure, where switch I region moves away from the nucleotide-
binding site145,146. Extensive interaction of the GEF with switch II region 
ensures that the nucleotide-free GTPase is stable145,146, but also 
contributes to the family-specificity of the GEF-GTPase interaction that is 
observed for RhoGEFs147. These conformational changes disturb the 
BA
Figure 4 Mechanism of GEF-mediated nucleotide exchange and GAP-induced GTP 
hydrolysis. A) Schematic representation of  the common mechanistic principle of GEF-
mediated nucleotide exchange. GEF domain binding causes a conformational change of the 
GTPase where switch I is moved away from to the nucleotide-binding site, whereas switch II is 
moved to the nucleotide-binding site. The hydrophobic repulsion by the conserved alanine (Ala) 
in the GEF pushes the Mg2+ ion out of position, reorienting the lysine (Lys) in the p-loop toward 
the carboxylates in  switch II region. The β-phosphate of GDP is no longer stabilized and 
accordingly released first followed by the base. B) During the GAP-catalyzed GTP hydrolysis the 
conserved arginine (Arg) in the GAP neutralizes the negative charge on the γ-phosphates 
during the transition state.  The arginine-stabilized invariant glutamine in the switch II domain 
of the GTPase serves as catalytic site for the in-line nucleophilic attack of a water molecule on 
the γ-phosphate of the GTP. Asp, aspartic acid; Gln, glutamine; Glu, glutamic acid; GTPase, 
Ras/Rho GTPase; P, phosphate; SI, switch I region; SII, switch II region; GEF, Ras/Rho GEF 
domain; GAP, Ras/Rho GAP domain. (Image adapted from Vetter and Wittinghofer2 and Bos, 
Rehmann and Wittinghofer5.) 
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interaction of the conserved lysine from the phosphate binding-loop with 
the β-phosphate of GDP. In the case of Ras/Sos, but not for Arf/Sec7, the 
resulting hydrophobic repulsion created towards the Mg2+ ion, enhanced 
by the alternative positioning of the conserved alanine, further lowers the 
affinity towards the GDP148. In the new configuration the phosphate 
groups of the nucleotide will no longer be stabilized and accordingly be 
released first, followed by the base145,148. Small GTPases generally do not 
discriminate between GDP and GTP in terms of binding affinity, but, 
because of the excess of cellular GTP over GDP149, the release of bound 
GDP is followed by subsequent binding of the more abundant GTP. The 
new nucleotide will bind base first to the nucleotide-free GTPase and, as a 
result weaken the affinity for the GEF, subsequently displacing it 
altogether.  
 
For most GTPase families the number of GEF proteins is approximately 
the same as the number of GTPase proteins. However, the Rho subfamily 
forms an exception to this rule, as the GEFs outnumber the GTPase 
proteins 4:1150. The most studied Ras- and RhoGEF proteins are 
characterized by the CDC25 homology domain, often in combination with 
a Ras exchange motif (REM), and the Dbl homology (DH) and pleckstrin 
homology (PH) domains, respectively, which together provide the minimal 
structural unit that is necessary for GEF activity and target GTPases 
recognition as well as cellular localization136,151-154. In addition to the 
tandem DH-PH domain containing RhoGEFs, a second, structurally and 
mechanistically different, subfamily of RhoGEF exists that contains a Dock 
homology region (DHR) domain155. This subfamily of RhoGEFs catalyzes 
the nucleotide exchange reaction of Rac and/or Cdc42, but not RhoA 
(reviewed in [156,157]).  
 
In addition to the domains forming the minimal structural unit, GEF 
proteins typically contain protein-specific domains that define the unique 
cellular functions of the different family members by regulating their 
localization, formation of signaling complexes and /or activation5,157. This 
essential diversity in domain structures is best illustrated by the 
promiscuity of the RhoGEFs; there is a large set of RhoGEFs that can 
activate RhoA, Rac1 and Cdc42 in vitro, yet in vivo each GEF activates 
their target GTPases in a pathway specific manners157,158. For example, 
specific phosphorylation of Tiam1 by mitotic kinase cyclin-dependent 
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kinase 1 (Cdk1) primarily results in the Rac1-mediated activation of 
PAK1/2159, whereas Rac1 activation by Vav primarily results in the 
activation of the JNK cascade160,161.  
 
These additional domains, as well as the PH domain in RhoGEFs, control 
activation by providing a mechanism for intramolecular inhibition as they 
fold around the catalytic domain and prevent interaction with the GTPase. 
To illustrate, the active site of nonphosphorylated Vav proteins162 is 
obstructed by its N-terminal CH-Ac region that is folded over catalytic 
core163. Upon phosphorylation of tyrosine residue 174, by Src and Syk 
kinases164-166, the inhibited structure is relieved163. In fact, using NIH3T3 
fibroblast transformation assays167, most GEF proteins, e.g Dbl168, Vav169, 
Tiam138 and epithelial cell transforming sequence 2 (Ect2)170, were 
originally discovered from human tumor-derived DNA as amino-terminal 
truncated, activated versions of the normal gene product that were able 
to demonstrate transforming properties, such as the loss of density- 
dependent growth inhibition as well as form colonies in soft agar, and, 
therefore, dubbed oncogenes. 
 
 
?????????????????????????????????
The intrinsic GTPase activity of small GTPases is generally slow and GAPs 
are required to stimulate the GTP-hydrolysis activity, which in turn 
inactivates small GTPase signaling5,134,171,172. For Rho and Ras GTPase 
proteins, in vitro GTP hydrolysis occurs at higher rates than nucleotide 
exchange. While the nucleotide exchange rate is increased by GEFs in 
vivo, in resting cells, only low levels of GTP-bound small GTPases are 
found, which implies that GAPs actively maintain GTPase-mediated 
signaling173.  
 
GAPs can be seen as effectors, regulating signaling by specifically turning 
off pathways. Rac1-mediated activation of GIT1, an Arf GAP, results in 
the decrease of active Arf6 and subsequent recycling of clathrin-
independent endosomes174. By turning off pathways, competitive 
pathways can become active. Rac1 activity is suppressed by MgcRacGAP, 
which is shown to result in increased activity of RhoA driving invasive 
migration event175. Furthermore, oncogenic Ras mutants not only have an 
impaired intrinsic GTP hydrolysis, the oncogenic transformation by 
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constitutive activation is mainly driven by the loss of GAP-mediated 
inactivation176, illustrating that turning off pathways is as important as 
turning them on.  
 
Like GEF proteins, GAP proteins are not conserved between different 
GTPase families. Accordingly, the reaction mechanism by which GAP 
proteins stimulate the GTP-hydrolysis reaction is different between 
families of small GTPases (reviewed in [134]). However, the tertiary 
structure as well as the mechanism of the GAP-assisted hydrolysis was 
found to be similar for Ras and Rho GTPases177.  
 
During the GAP-stimulated hydrolysis, the 20-50 kDa GAP domain 
provides an arginine residue, the so-called arginine finger178,179. The 
arginine finger neutralizes the negative charge on the γ-phosphate during 
the transition state, as well as stabilizes the position of a conserved 
glutamine in the switch II domain of the GTPase (residue 61 in Ras and 
63 in Rho) (Figure 4). The conserved glutamine serves as catalytic site 
for the in-line nucleophilic attack of a water molecule on the γ-phosphate 
of the GTP.  
 
Whereas it has been shown that GEF-mediated nucleotide exchange is a 
multistep process, it is unclear whether GAP-GTPase association and 
arginine finger positioning are two separate steps. In case of p50RhoGAP 
and Cdc42, two different orientations of the arginine finger have been 
shown179,180, which would indicate it may be a multistep process. While 
recent work addressing this issue could not answer this as yet, the 
derived data supports a general concept for GAP-mediated GTP hydrolysis 
in which any residue that can be moved into the binding pocket and drive 
out the water molecules would be able to stimulate the GTPase 
reaction172.  
 
The GAP domain alone is sufficient for both the binding to, as well as 
stimulating the GTPase activity of GTP-bound GTPase proteins181, which 
implies that the multidomain GAPs are, like GEF proteins, regulated 
through the flanking domains. The majority of flanking domains is 
restricted to one or two subfamilies of GAP proteins, with the exception of 
the most common motifs, the SH3 domain and PH domain (reviewed in 
[171]). For each GTPase family, there are less or as many GAPs as 
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GTPase proteins, except for the Rho family, where the GAPs outnumber 
the GTPase proteins 3:1150. Accordingly, the most diverse set of flanking 
domains is found in the RhoGAP family, suggesting a diverse variety in 
regulating mechanisms.  
 
Flanking domains are involved in e.g. protein-protein interactions, 
protein-lipid binding and intramolecular inhibition, as well as provide 
protein kinase phosphorylation sites. For example, during metaphase the 
GAP activity of MgcRacGAP is sequestered while in complex with protein 
regulator of cytokinesis 1 (PRC1)182. Phosphorylation of the N-terminal 
region of MgcRacGAP by Aurora B kinase results in the loss of the protein-
protein mediated inhibition182. A more complex mechanism of regulation 
has been found for β2-chimaerin183, a RhoGAP consisting of an N-terminal 
SH2-domain that sterically blocks the adjacent C1-domain as well as the 
C-terminal GAP-domain. Membrane interaction leads to a large 
conformational change of the protein, which subsequently enables 
diacylglycerol (DAG), a second messenger signaling lipid, to compete with 
the N-terminal segment that is otherwise tightly bound by the C1-domain. 
Upon binding of DAG, the N-terminal segment is displaced and no longer 
inhibits Rac binding. Furthermore, it is believed that other GAPs, like 
GEFs, reside in a folded conformation that provides an intramolecular 
inhibition or reduces the GAP activity, though the mechanism of 
autoinhibition are much less well understood than for GEFs.  
 
 
?????????????????????????????????????????????????
Most small GTPases require association with cellular membranes in order 
to perform their biological functions. The addition of a lipid moiety is not 
only crucial for the membrane anchoring, but also provides the third 
mechanism of regulation (Figure 1). Guanine nucleotide dissociation 
inhibitors (GDIs) were initially thought to block spontaneous activation of 
small GTPases, thereby stabilizing the inactive form184. However, GDIs 
have only been found in the Rho and Rab families of small GTPases134,150. 
In addition to the Rho and Rab GDI proteins, another regulatory protein 
with a similar function was more recently found for Ras GTPases; the 
delta subunit of retinal rod phosphodiesterase (PDEδ), which can extract 
farnesylated Ras proteins from the membrane185,186. Current knowledge 
suggests that these regulatory proteins actively extract prenylated 
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GTPases, either GTP- or GDP-bound, from the membrane by forming 
high-affinity complexes, thereby sequestering their target GTPases in the 
cytosol, which as such are unable to interact with their membrane bound 
effectors109,134,187,188. More specifically, Rab GDIs function as regulating 
chaperones, extracting Rab proteins from the acceptor membrane, recycle 
them to the cytosol and delivering them back to the donor membrane189.  
 
The Rho and Rab GDI proteins are unrelated, but both function through a 
two-site interface with the target GTPase134,187, which is illustrated with 
the following RhoGTPase example. The N-terminal domain of the RhoGDI 
recognizes the switch region of the GTPase, which affects the GDP–GTP 
cycling. The C-terminal domain interacts with the prenylated C-terminus 
of the GTPase, binding the lipid tail in its hydrophobic pocket and thereby 
regulating the membrane / cytosol distribution. Unlike the Rho and Rab 
GDI proteins, PDEδ lacks a GTPase binding domain134,185. Accordingly, 
binding of Ras GTPases by PDEδ occurs through a single domain that is 
structurally related to the RhoGDI lipid-binding domain134,185. As a result, 
PDEδ is less specific than Rho and Rab GDI proteins, and has been 
reported to be able to interact with non-prenylated proteins such as Arf 
GTPase Arl3185.  
 
While the lipid moiety is docked in the hydrophobic pocket, it is believed 
that the more diverse C-terminus of the GTPase is not completely 
masked190. With the exposed part, the GTPase is able to interact with 
adaptor proteins in the cytosol or at the plasma membrane190. As a result, 
Rho and Rab GDI proteins can be specifically regulated by kinase-
mediated phosphorylation of the GDI and GDI displacement factors 
(GDFs)188,190. To illustrate the first, phosphorylation of RhoGDI by PAK1 
results in the release of Rac1, but not RhoA or Cdc42191. In the second 
case, GDFs possess, like GDIs, a hydrophobic pocket that can bind a lipid 
moiety. When the Rab-GDI complex is back at the donor membrane, 
where the GDFs are located, the Rab prenyl tail will transfer from the GDI 
to the GDF, leaving Rab at the membrane in complex with GDF189. In both 
cases, the GTPase will dissociate from the GDI, generally resulting in GEF-
mediated activation of the GTPase and initiation of downstream signaling.  
 
 
 
 29
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GEF and GAP proteins are regulated through phosphorylation and 
subsequent dephosphorylation by kinases and phosphatases, respectively. 
However, it has been shown that also GTPases are regulated by 
phosphorylation/ dephosphorylation, with examples found in almost all 
GTPase families, such as RhoA192,193 and Cdc42194, Rab24195, Ran196 as 
well as R-Ras197 and Ras198-200. Paradoxically, Ras-mediated Raf signaling 
is terminated by the GAP-stimulated hydrolysis, while Raf binds to Ras 
with a nanomolar affinity15, many fold greater than that of RasGAPs 
p120RasGAP and neurofibromin (NF-1) (0.1-10 µM)201. Phosphorylation of 
Ras Y36 enables the GAP to compete off the Raf and shutting down Ras 
signaling198. Vice versa, dephosphorylation of Ras by tyrosine-protein 
phosphatase non-receptor type 11 (also known as SHP-2) enhances Ras 
association with Raf and enables downstream signaling199. While similar 
regulatory mechanisms have been found for most other small GTPase 
families194-197, it is still too early to conclude whether this is a small 
GTPase wide mechanism that should be incorporated in the traditional 
GTPases cycle (Figure 1) as regulatory node. For example, the 
phosphorylation of RhoA S188 seems to represent an extra switch that 
dedicates what specific downstream signaling pathways to activate193, 
rather than controlling the on/off switch. 
 
GTPases, together with GEFs, GAPs and GDIs, function as the signaling 
nodes for many pivotal regulatory pathways. These pathways are not 
parallel sequential cascades, but rather highly integrated signaling 
networks, where, under tight temporal control and distinct spatial 
distribution, different pathways can function separately, but also interact 
with one and other. Thus, a defect in the GTPase regulatory system can 
be compensated by redundancy, but for key nodes, alterations can have 
devastating results.  
 
 
 
????????????????????????????
 
Due to the role of small GTPases in a variety of essential cellular 
processes, aberrant function and/ or regulation has long been associated 
with multiple human diseases, like various forms of cancer, 
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neurodegenerative diseases, cardiovascular diseases, endocrine diseases 
and inflammatory disorders1,4,8,150,202-206. In the majority of cases, 
uncontrolled activation of the GTPase causes aberrant downstream 
signaling. There are four mechanisms that cause an accumulation of 
activated GTP-bound GTPase; i. increased GEF activity, ii. decreased GAP 
activity, iii. mutations in the small GTPase causing an impaired intrinsic 
GTP hydrolysis ability (Figure 1), and iv. overexpression of the GTPase. 
 
Advances in genome sequencing have made it possible to identify and 
map all occurring sequence abnormalities and mutations in cancer. The 
most commonly found driver mutations, found in approximately 30% of 
all human cancers, result in the mutationally activated variants of the Ras 
GTPases207,208. In the three RAS genes, two hot spots have been 
identified at codon positions 12-13 and 61, coding for the tandem glycine 
glycine in the P-loop and the conserved glutamine in switch region II of 
the Ras proteins, respectively (Figure 5A). During the GAP-mediated 
hydrolysis reaction, the arginine finger is inserted into the GTPase along 
side of glycine residue 12178. Since glycine is the smallest amino acid, any 
mutation will introduce a more bulky amino acid, generating a mutant 
that is insensitive to hydrolysis because the arginine finger can no longer 
be inserted. The glutamine at residue 61 is also involved in GTP 
hydrolysis, where it serves as the catalytic site for the in-line nucleophilic 
attack178,179. Accordingly, oncogenic mutations of codon 61 reduce the 
intrinsic GTP hydrolysis rate and, like the oncogenic mutations at position 
12-13, result in a constitutively active Ras protein (Figure 5B).  
 
Interestingly, the incidence of RAS mutations is not only spread 
differentially over the isoforms, each isoform has a distinctive codon 
mutation signature as well as tissue-specific associations207,208. For 
example, in Ras-driven cancers the KRAS isoform is most frequently 
mutated (>85%), followed by NRAS (~10%) and HRAS (<5%)209 (Figure 
5C). Mutations in the KRAS gene occur predominately at codon 12 and 
only a few mutations are observed at codon 61, whereas mutations in 
NRAS are found twice as often at codon 61 compared to codon 129,208,209 
(Figure 5C). Last, generally only a single mutant isoform is observed in 
different types of cancer tissue, e.g. pancreatic ductal adenocarcinoma 
seems exclusively driven by the KRAS mutations, while malignant 
melanoma is predominately driven by NRAS mutations207,208.  
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Figure 5 Oncogenic mutations of Ras and isoform specific mutation bias. A) The three key 
oncogenic mutations, at codon 12, 13 and 61, occur in the region where the Ras isoforms are 
identical. Visualized in the schematic representation of the Ras protein are; the nucleotide binding 
domains (G1-5, gradient black), the effector binding domain (residues 32-40, pink), the switch 
regions (S1 and SII) and the hypervariable region (HV, blue). Below is given the isoform sequence 
similarity percentage between the Ras isoforms with in subscript the corresponding regions by 
amino acid numbering. B) The oncogenic mutation at codon G12, G13 and Q61 impair GAP-
stimulated GTP hydrolysis resulting in a constitutively active Ras protein. C) The approximate 
frequencies of Ras mutations by isoform (bigger circle more mutations found) and by codon 
(colors of the pie chart). (Image adapted from Cox and Der209 and Prior, Lewis and Mattos208.) 
 
In contrast to the high oncogenic mutation rates in RAS encoding genes, 
RHO genes are rarely mutated in cancer210. Only two mutational hotspots 
have been found and, remarkably, they are at different locations of the 
GTPase protein than the Ras oncoproteins; one causing a so-called fast-
cycling mutant of Rac1 (P29S) in melanoma211,212 and the other inducing 
a dominant negative loss-of-function for RhoA (G17V) in gastric 
cancer213,214, as well as in angioimmunoblastic T cell lymphomas215,216. 
Instead, recent reviews have shown that Rho GTPase activation is 
generally a result of deregulated gene expression1,210, and/ or 
(mutationally) altered RhoGEF and/or RhoGAP activity4,158. Of note, in 
addition to mutational activation, upstream deregulation also happens for 
???
?? ?
??
???
???
???
??????
Effector
???
????????
???
???
???
100%1-85
SI32-38 SII60-76
G110-17 G235 G353-62 G4112-119 G5144-146
HV
G12 G13 Q61
90%86-165 15%166-188/9
N CRas
B
A
G12
G13
Q61
Other
K-Ras N-Ras H-Ras
C
 32
Ras GTPases, where loss-of-function mutations in the p120RasGAP and 
NF-1 RasGAPs, as well as gain-of-function mutations in RasGEF Sos1 
cause Ras hyperactivation in different Ras-related diseases8,9,134.  
 
Mouse models have shown that the deregulation of Rho GTPases in 
embryonic development leads to severe developmental defects, with Rac1 
and Cdc42 as well as regulators Sos1, Trio and Ect2 deficient mice being 
embryonic lethal158,217. It is clear that in development these proteins are 
essential for normal physiology, but aberrant expression later in life 
results in reactivation of small GTPase-regulated developmental 
pathways, like Wnt218, Notch219, and Hegdehog220,221.  
 
A recent study identified chromosome 3q26 to be frequently amplified, 
estimating that copy number gains occur in about 20% of human 
tumors222. Located on chromosome 3q26 are, amongst others, genes that 
encode for Ect2, p110α subunit of PI3K, protein kinase C iota (PKCi) and 
transcription factor SOX-2. Interestingly, most of these proteins have a 
role in different Rac GTPase signal transduction pathways. GTP-bound Ras 
binds to and signals through p110α subunit of PI3K53,54, whereas PI3K 
activates Rho GTPase regulatory proteins105,106, and as such mediates 
activation of Rac1. Work from different labs has shown that Rac1 is 
required for Ras induced tumorigenesis in different type of cells223-225. 
Moreover, it was shown that the complex of PKCi and partitioning 
defective homolog (PAR) 6α regulates the cytoplasmic localization of Ect2, 
also leading to Rac1 activation and subsequently inducing cellular 
transformation of non-small cell lung cancer226. These findings are largely 
in line with earlier observations describing that Ect2 cytoplasmic 
mislocalization results in the activation of Rho GTPase signaling, though 
RhoA was predominately activated, and leads to malignant transformation 
of NIH 3T3 cells227. Consistent with the latter results is the report that 
cytoplasmic Ect2 preferentially activates RhoA228. On the other hand, this 
same study showed that not cytoplasmic Ect2, but the localization of 
phosphorylated Ect2 to the nucleus and the subsequent activation of Rac1 
drives ovarian cancer cell transformation. Of note, in interphase the Rac1 
specific GAP MgcRacGAP is also localized in the nucleus229. Furthermore, it 
was demonstrated that inappropriate activation of PKCi resulted in the 
activation of pro-survival transcription factor proteins, such as STAT3 and 
transcription factor p65 (also known as NF-κB). Interestingly, interactions 
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between MgcRacGAP, GTP-bound Rac1 and STAT3 have been described, 
but I will return to this in section 2.4.  
 
Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger (P-
Rex) 1 and 2 are RhoGEFs that primarily activate Rac1, thereby mediating 
Rac signaling downstream of G protein-coupled receptors and PI3K230-232. 
P-Rex1 overexpression has been reported in melanoma cell lines as well 
as human tissue, driving invasion in a Rac-dependent manner233. Another 
study identified P-Rex2 to be frequently mutated in human melanoma 
and, to demonstrate the functional relevance, missense and truncation 
mutants were expressed in TERT-immortalized NRAS mutant human 
melanocytes, transplanted into immunodeficient mice and shown to 
increase the rate of tumor formation234. Given that Rac1 mutants are 
found exclusively in melanoma211,212, it underscores the important driver 
function of Rho GTPase mediated signaling in cancer. 
 
 
 
????????????????????????????????????????????????????????????????
 
With the profound role of GTPase in biology and uncontrolled GTPase 
activation driving aberrant downstream signaling, it is interesting to be 
able to control GTPase signaling. In the following section I present an 
overview of small molecule inhibitors that have been developed to target 
different nodes of small GTPases regulation (Figure 6). Furthermore, I 
aim to address the wide range of screening methods used and different 
mechanisms of inhibitory activity that have been discovered (see Table 
1). The overview is primarily focused on compounds modulating Ras and 
Rho GTPase signaling. 
 
 
????????????????????????????????
In general, there are two major strategies for drug discovery. Most of the 
compounds that will be discussed have been discovered through so-called 
“bottom-up” approaches, starting at the protein level. Through drug 
discovery history these bottom-up approaches have been immensely  
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Table 1 Overview GTPase activity modulating compounds discussed in this thesis. N.a., 
not applicable;  
Name Target Assay type Ref. 
Rhodblocks Rho pathway Phenotypic screening  235 
ML141  Cdc42  Flow cytometry bead-based assay 236-240
 
EHT-1864  Rac Phenotypical screening assay 241,242 
NSC23766  Rac1-Trio/Tiam1 Structure-based virtual screening  243
 
ZINC69391  Rac1-Tiam1 Docking-based virtual screening  244
 
1A-116 Rac1-Tiam1 Rational design based on ZINC69391 244
 
ITX3 Rac1/ RhoG-Trio Yeast exchange assay  245,246 
EHop-016 Rac1-Vav2 Rational design based on NSC23766  247,248 
AZA1  Cdc42/Rac1-GEF Rational design based on NSC23766  249,250 
AZA197  Cdc42-GEF Rational design based on NSC23766  249,250 
ZCL278 Cdc42-GEF Docking-based virtual screening  251
 
Rhosin  Rho Docking-based virtual screening  252
 
Brefeldin A  Arf1-Sec7 Cell-based protein synthesis assay 253,254 
N.a.a Ras-Sos Homogeneous time-resolved 
fluorescence  255 
N.a.a Ras-Sos Fragment-based using NMR 256
 
DCAI (/DCIE) Ras-Sos Fragment-based using NMR 257
 
N.a.a Ras-Raf Phenotypical screening assay  258
 
MCP 
compounds 
Ras-Raf Yeast two-hybrid screen  
259
 
Kobe 
compounds 
Ras-Raf In silico screening 
260
 
4M22 Ras/ Ras-Sos Tethering 261
 
ARS-853  Ras/ Ras-Sos Mutant specific LC/MS-MS–based 
assay 262 
SML 
compounds 
Ras/ Ras-Sos 
 
Rational design based on GDP 
scaffold 263,264 
fasudil 
(HA1077) 
ROCK Compound screening in canine 
model 265,266 
ripasudil ROCK Compound screening in rabbit model 267
 
PF-3758309 PAK Rational design based on preceding 
data 268 
Phox-I1  Rac1/2-p67phox Structure-based virtual screening  269
 
lonafarnib  Farnesyl transferase In vitro enzyme assays 270,271 
tipifarnib?? Farnesyl transferase N.a. n.a. 
deltarasin PDEδ  AlphaScreen  272,273 
 
a.  Multiple compounds were identified in this screen, but not given names. 
b. Tipifarnib was developed by Johnson & Johnson, no reports are available in scientific 
literature describing the initial discovery and the methods used. 
?
 ?
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Figure 6 Nodes in the small GTPase cycle targeted for drug discovery. There are several 
regulatory nodes in the GTPase cycle that have been exploited for small molecule-mediated 
modulation; 1) lock GTPase in GDP-bound state, 2) block GEF-mediated nucleotide exchange, 3) 
compete with GTP for nucleotide binding pocket, 4) disrupt GTPase-effector binding, 5) inhibit 
downstream effector signaling, 6) target posttranslational modification, e.g. the addition of a 
farnesyl group by farnesyl transferase (FTase) and 7) interfere with the regulatory function of 
GDIs. GAP, GTPase activating protein; GDI, guanine–nucleotide-dissociation inhibitor; GDP, 
guanosine diphosphate; GEF, guanine exchange factor; GTP, guanosine triphosphate Pi, inorganic 
phosphate. 
 
useful in identifying potent and selective compounds, however they have 
always suffered from three distinct problems; i. they are limited to 
measurable functions of a protein, for example enzymatic activity, ii. in 
vitro successes do not guarantee in vivo activity as a compound can 
exhibit poor cell permeability and iii. unexpected off-target cellular effects 
might not be easily diagnosed274.  
 
The opposite strategy, the “top-down” approach, starts at the phenotypic 
level and circumvents these challenges. However, phenotypic screening 
generally experiences challenges in distinguishing observable phenotypes. 
In case of the Rhodblock compounds235, a screening strategy was used 
that was analogous to a genetic modifier screen; cells were sensitized 
using RNA interference (RNAi) to impair signaling through the Rho 
pathway and subsequently treated with small molecules. As a result of 
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the partial depletion of Rho, cytokinesis was successful only in half of the 
cases. Compounds that suppressed or enhanced the phenotype, meaning 
either increased success or failure of cytokinesis, respectively, were 
selected for follow-up secondary assays and target identification. By this 
screening approach nine so-called Rhodblock inhibitors were discovered 
that have different targets within the Rho pathway in cytokinesis. One 
compound, Rhodblock 6, directly interfered with the Rho pathway activity 
by inhibiting Rho kinase. The other compounds indirectly interfered. For 
example, Rhodblocks 1a and 3 disrupted the important scaffolding 
functions of Rho-regulated proteins, such as Anillin and the septins, 
resulting in the mislocalization of several important Rho pathway proteins 
and decreased Rho pathway activity. While these compounds can be used 
to gain insight in the Rho pathway, the exact targets for most are 
unknown, making it more challenging to improve them to clinically 
relevant compounds.  
 
 
????????????????????????????????????
The crucial role of GTP-bound GTPases in oncogenic transformation 
marked them as potential therapeutic target in cancer. Accordingly, early 
studies aimed to inhibit GTP binding by nucleotide-competitive small 
molecules, in a similar way that protein kinase inhibitors were designed to 
compete for binding with adenosine triphosphate (ATP). In contrast to 
protein kinases, which typically show micromolar binding affinities toward 
ATP, most small GTPases have picomolar affinity toward guanine 
nucleotides, making them challenging targets for nucleotide-competitive 
small molecule inhibitors12.  
 
Nevertheless, two Rho family inhibitors that interfere with the nucleotide 
binding have been identified. Through an NIH Molecular Libraries Program 
screening campaign (PubChem AID 1772), using a multiplex flow 
cytometry bead-based assay, several lead compounds were identified that 
interfered with GTPase nucleotide binding236-240. In particular, one class of 
these modulators was identified as selective Rho family GTPase Cdc42 
inhibitors, with compound ML141 triggering nucleotide release and locked 
Cdc42 GTPase in an inactive confirmation, thus interfering with Cdc42-
dependent cellular processes such as formation of filopodia238,240. 
Furthermore, originally found as an inhibitor of β-amyloid processing, 
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EHT-1864 was shown to block the Rac1 signaling pathways241,242. A 
subsequent study of the mechanism of action revealed that, as a 
nucleotide binding inhibitor of all Rac GTPases isoforms, EHT-1864 
blocked GEF-mediated nucleotide exchange, preventing downstream 
effector binding and thereby inhibited Rac-dependent processes in 
cells275. To-date, due to the high affinity of small GTPases towards their 
nucleotides, no clinically relevant nucleotide-competitive small molecules 
have been developed.  
 
 
???????????????????????????????????????????
As a result of the high affinity of small GTPases towards their nucleotide, 
GEF proteins are required to accelerate the slow intrinsic exchange 
reaction in vivo5,134. Accordingly, a common strategy to inhibit GTPase 
activation is to interfere with the small GTPase-GEF interaction. However, 
Ras GTPases are frequently mutationally activated (reviewed in 
[207,208]) and, as a result, impaired in their ability to hydrolyze GTP 
allowing these mutants to remain in active GTP-bound state even in the 
presence of a GAP178. Inhibiting GEF-mediated activation is only 
interesting, if the target GTPase has the ability to hydrolyze GTP. Rho 
GTPases are rarely mutated, and their activation is often a result of 
deregulated expression and/ or upstream activity of (mutated) 
regulators1,158,210,276. Therefore, I will largely focus on inhibitors of 
GTPase-GEF interaction concerning the Rho GTPase family and to a lesser 
extend on the Ras GTPase family. 
 
Rho GTPase proteins contain a ridge between two shallow pockets within 
the GEF binding area that determines the unique GEF specificity (F56 of 
Cdc42, W56 in Rac1)277,278 The importance of the surface groove was 
exploited for a series of virtual screening campaigns, which identified 
Rac1-GEF interaction inhibitors NSC23766243 and ZINC69391244 as well as 
Cdc42-GEF specific inhibitor ZCL278251. NSC23766 dose-dependently 
inhibited Rac1 activation by the Rac1 W56-interacting Rac-selective GEFs 
Trio and Tiam1243, yet had no effect on nucleotide exchange activity 
stimulated by the promiscuous GEF Vav1, which does not interact with 
W56277. The interaction between other Rho proteins, such as RhoA and 
Cdc42, and their GEFs or the interaction between Rac1 and the GAP 
breakpoint cluster region protein (BCR) was also not affected by 
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NSC23766. ZINC69391 was identified and served as lead inhibitor for the 
subsequent rational design of analog 1A-116244. 1A-166 was shown to 
inhibit Rac-mediated cell proliferation in normal full growth media 
condition as well as to reduce of lung colonization in mice. ZCL278 is a 
low micromolar inhibitor of the interaction between Cdc42 and its GEF 
intersectin251. In vitro, ZCL278 inhibits Cdc42-mediated microspike 
formation, reduces the amount of active Cdc42 in fibroblast cell cultures 
as well as suppresses actin-based motility and wound healing in a 
metastatic prostate cell line. A similar recognition motif is present around 
residue W58 of RhoA and is only shared with close relative isoforms RhoB 
and RhoC252. A virtual screen that was designed to identify compounds 
binding around residue W58 identified Rho-specific inhibitor Rhosin. In 
cellular assays Rhosin inhibited Rho-specific downstream signaling, but 
did not affect Rac1 or Cdc42 downstream signaling.  
 
Instead of screening, using previously published molecules as lead 
compound and subsequently improve biochemical properties has proven 
to be feasible. The optimization of NSC23766 by rational design led to the 
identification of EHop-016, an inhibitor that binds the effector domain of 
Rac1 and inhibits Rac1 activity at physiologically relevant concentrations 
of 1 µM247,248. Unlike NSC23766, EHop-016 reduces the interaction of 
RhoGEF Vav2 with Rac1, with only modest activity towards Cdc42 and 
none towards RhoA247. Furthermore, EHop-016 was shown to significantly 
reduce mammary fat pad tumor growth, metastasis, and angiogenesis in 
a nude mouse model of experimental metastasis248.  
 
While rational design using NSC23766 as lead compound has generated a 
Rac-specific inhibitor EHop-016, similarly derived close related analogs 
AZA1 and AZA197 showed altered selectivity249,250. AZA1 was shown to 
inhibit the GEF-mediated activation of both Cdc42 and Rac1, but not 
RhoA, in dose-dependent matter250. Notably, AZA1 restrained proliferation 
and cellular migration of prostate cancer cells as well as reduced growth 
of human xenografts in mice. On the other hand, AZA197 was shown to 
be selective towards Cdc42249. Using colon cancer cells, it was 
demonstrated that AZA197 specifically inhibited nucleotide exchange of 
Cdc42, without inhibition of Rac1 or RhoA GTPases. Like AZA1, AZA197 
treatment inhibited cancer cell proliferation and migration as well as 
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reduced downstream signaling though PAK1 in vitro and significantly 
increased mouse survival in tumor xenografts models.  
 
ITX3, a specific inhibitor of Rac1 activation by Trio, was identified through 
a screening procedure using a yeast exchange assay to select inhibitors 
that specifically block the activation of RhoG by TrioN, the N-terminal GEF 
domain of the multidomain protein Trio245,246. In vitro, ITX3 inhibited 
nucleotide exchange on RhoG and Rac1, as well as nerve growth factor-
induced neurite outgrowth in PC12 cells, a process that is mediated by 
the N-terminal RhoG and Rac1-targeting domain of Trio. However, the 
compound is only effective at high >50 µM concentrations.  
 
Two independent studies using different NMR-based fragment library 
screening approaches, identified the same novel hydrophobic pocket 
between switch regions I and II of Ras256,257. One of the hit compounds, 
DCAI, was shown to bind to Ras and inhibit Sos-mediated nucleotide 
exchange by blocking the interaction between Sos and Ras257. The binding 
to Ras did not affect the intrinsic nucleotide exchange by Ras. Notably, 
half maximal effective concentration (EC50) values derived from cell-based 
experiments, e.g. EGF-stimulated Ras activation as well as subsequent 
recruitment of Raf to the cytoplasmic membrane, were a full log-fold 
more potent than the biochemical assays, raising concerns about possible 
off-target driven effects.  
 
 
????????????????????????????? ?????????????????????????????????????????
The concept of interfacial inhibition utilizes the dynamic behavior of 
protein complexes and the ability of small molecule compounds to bind at 
such interfaces with high selectivity locking the complex in one state. The 
natural compound Brefeldin A inhibits the activity of the Arf GEF Sec7 by 
stabilizing the complex between Sec7 and Arf1, thereby blocking 
nucleotide exchange253,254. Brefeldin A is a prototypical interfacial 
inhibitor, locking the complex of macromolecules in a nonproductive 
transition state that is unable to fulfill its biological function279,280. This 
mode of inhibition is distinct from the previous compounds, which inhibit 
the interaction between small GTPase and GEF.  
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Though efforts have been made, only a handful of these compounds have 
been described to date. In case of Ras GTPase, a fragment screening 
campaign using X-ray crystallography was performed and three district 
small molecule binding sites were identified at the interface between H-
Ras and Sos255. However, the ligands identified to bind reversibly to the 
Ras-Sos complex were not sufficiently potent to show measurable 
stabilization of the complex. While the interfacial inhibitory compounds 
identified were not sufficiently potent, the reactive compounds that 
covalently bound to residue C118, were shown to completely inhibit K-
Ras-Sos functional activity255.  
 
 
????????????????????????????? ????????????
Inhibition by covalent modification is successfully used by nature to inhibit 
GTPase signaling, exemplified by the bacterial toxin C3 transferase that 
inactivates RhoA by ADP-ribosylation281. C3 transferase is commonly used 
to study the role of RhoA in cellular systems. Covalent inhibitors SML-8-
73-1 and SML-10-70-1 were discovered by using a design based on the 
GDP scaffold, targeting the nucleotide binding site of K-Ras G12C and 
block binding to GTP263,264. Docking of the compound in the nucleotide 
binding pocket brings the reactive moiety of the compound close to the 
neighboring mutant-specific cysteine residue and subsequently forms a 
covalent bond with the cysteine residue. In the resulting conformation, 
which resembles the inactive GDP-bound state, Ras is unable to interact 
with effector proteins263.  
 
A novel approach in both attempting to block mutant Ras signaling as well 
as screening for small GTPase inhibitors was applied in the discovery of 
the covalent inhibitor 4M22261. First, the screening was based on a 
method called tethering282, utilizing the cysteine residue of non-small-cell 
lung cancer specific KRAS mutant (K-Ras G12C) to irreversibly bind small 
molecule compounds to the target protein. Using a K-Ras construct 
lacking other cysteine residues (K-Ras G12C/C51S/C80L/C118S), a 
chemical starting point was identified from a small library of 480 
‘tethering compounds’ and subsequently exploited to generate analogs 
through X-ray structures of co-complexes. Second, 4M22 and analogs are 
compounds that alter the nucleotide preference of Ras GTPase to favor 
GDP over GTP, thereby impairing binding to Raf. The ability of 4M22 to 
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lock K-Ras in GDP-bound state is achieved by targeting a recently 
discovered allosteric pocket under the Switch II loop region that is 
exposed exclusively in GDP-bound state.  
 
4M22 is very specific, as it was demonstrated to reduce cell proliferation 
and induce apoptosis in cell lines containing G12C mutations compared to 
cell lines lacking this mutation281. However, further characterization of 
4M22’s mechanism of action revealed low covalent engagement in 
heterozygous K-Ras G12C NCI-H358 cells262. Subsequent iterative 
structure-based design of covalent ligands targeting the Switch II pocket 
of K-Ras G12C led to the development of ARS-853, which showed a near 
complete inhibition of Ras-Raf interaction and downstream signaling 
through both the MAPK and PI3K signaling pathways at 1 µM262. 
Moreover, ARS-853 was demonstrated to inhibit oncogenic transformation 
in cellular assays at similar concentration. Of note, data provided by this 
study showed that K-Ras G12C activity levels are responsive to growth 
factor stimulation as well as inhibitory signals, strengthen the model that 
aberrant signaling of K-Ras G12C happens by “hyperexcitation”, rapidly 
cycling nucleotides in response to upstream signaling inputs. This 
warrants that aberrant signaling of Rho GTPases could be caused by a 
deregulated expression of both GEFs and GAPs.  
 
 
?????????????????????????????????????????????????
While the inhibition of GTPase-GEF activity might not be beneficial in the 
treatment of many Ras driven cancers, where different mutations prevent 
GTP hydrolysis, and interfacial inhibitors yet to be found, interfering with 
GTPase-effector binding presents an excellent opportunity to abrogate the 
downstream signaling events.  
 
The non-steroidal anti-inflammatory prodrug sulindac was used in cancer 
prevention and therapy283, before Müller and coworkers discovered that 
its metabolite, sulindac sulfide, binds to Ras and impairs downstream 
signaling284. Using a sulindac-derived compound library in a phenotypical 
screening assay based on the ability of H-Ras oncogene to transform 
Madine–Darby canine kidney cells, more potent analogs were 
identified258,285, and utilized to show that these compounds bind to Ras in 
a non-covalent manner near the switch I region, thereby inhibiting the 
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formation of the Ras-Raf complex286. Rigosertib (ON01910) was initially 
discovered following the synthesis of family of non-ATP competitive small 
molecule kinase inhibitors, which were screened for anti-proliferative 
properties on tumor cells and subsequently selected for potent inhibitory 
effect of polo-like kinase 1 (Plk1) activity287. Additional research has 
demonstrated that rigosertib is in fact a Ras-mimetic288, binding to the 
Ras binding domain (RBD) commonly found in many Ras effector 
proteins. Binding of rigosertib to the RBD of the effector proteins resulted 
in an inability to bind to activated Ras, and thereby inhibited multiple 
Ras-driven signaling pathways, including both PI3K289, as well as Raf290. 
In vivo studies, using xenograft models of human colorectal and lung 
cancers as well as genetically modified mouse model of pancreatic cancer 
containing the K-Ras G12D mutation, showed that rigosertib is a potent 
inhibitor of tumor growth. Furthermore, subgroups of myelodysplastic 
syndrome patients having cytogenetic abnormalities that are associated 
with Ras activation (monosomy 7 and trisomy 8)291,292 have responded 
best to treatment with rigosertib in a phase 3 randomized trial293.  
 
Other Ras-effector binding inhibitors were discovered through targeted 
screening approaches. Through a yeast two-hybrid screen another set of 
Ras-Raf inhibitor compounds were discovered259. This study, as well as 
the follow-up studies from different groups, showed that MCP compounds, 
notably MCP1, MCP53 and MCP110, inhibited Ras-induced Raf-1 
activation, reduced invasiveness and anchorage-independent growth in 
cells harboring K-Ras mutation, but not constitutively active Raf-1, and 
inhibited growth in human xenograft models for MCP110 in 
particular259,294,295.  
 
After solving the first complete tertiary structure of H-Ras, it became 
apparent that in GTP-bound state, Ras does possess well-defined surface 
pockets suitable for drug binding296. Subsequent in silico screening and 
biochemical characterization has identified Kobe0065 and its analog 
Kobe2602 to efficiently inhibit, both in vitro and in vivo, the binding of 
activated GTP-bound Ras with Ras-effector proteins260.  
 
With the possibilities to target GTPase-GEF activity, the need for Rho 
GTPase-effector inhibitors to perturb signaling might appear to be not as 
a necessity as for Ras GTPase proteins. Nevertheless, substantial effort 
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has been put in the discovery of Rho effector inhibitors, most notably Rho 
kinase and PAK inhibitors (reviewed in [297,298]). Interestingly, two 
ROCK inhibitors, fasudil and ripasudil, have been approved for clinical use 
in Japan and/ or China, whereas one PAK inhibitor, PF-3758309, made it 
to phase I clinical trials. Fasudil, HA1077, was discovered for having a 
potent vasodilator effect in a canine model, completely reversing the 
induced cerebral vasospasm266. While it was hypothesized the target 
would be a kinase265, it was not until a decade later that it was shown 
that fasudil was in fact a Rho kinase inhibitor299. Where fasudil 
demonstrated about equal potency towards both ROCK isoforms, the 
more recently discovered ripasudil displayed a slightly higher inhibitory 
effect towards ROCK2267. Results of preceding screening campaigns were 
used to rational design ATP-competitive, group II PAK inhibitor PF-
3758309268. PF-3758309 inhibits group II PAKs as well as group I 
member PAK1 at low nM concentration, whereas inhibition for other group 
I PAKs was observed in submicromolar range. Although significant tumor 
growth inhibition was observed in a panel of human xenograft models, 
clinical development of PF-3758309 has been put on hold as no tumor 
responses were observed in a phase I clinical trial300.  
 
Following the success of Rac inhibitor NCS23766, in silico screening has 
successfully been applied for Rho GTPase effectors as well269. Phox-I1 was 
discovered in an effort to identify inhibitors targeting the binding of the 
Rac1/2-p67phox, a pivotal event in the activation of NADPH oxidase, which 
is responsible for ROS production in neutrophils. In particular, Phox-I1 
and analogs displayed similar cellular ROS inhibitory activity in cultured as 
well as primary cells, without affecting the Rac-mediated actin 
cytoskeleton structure. 
 
 
????????????????????????????????????????????????? ????????????
The only GTPase-modulating compounds that have made it to clinical 
trails to date are the farnesyltransferase inhibitors lonafarnib270,271 and 
tipifarnib301,302. After synthesis, cytosolic Ras proteins are processed at 
the endoplasmic reticulum by prenyltransferases, which is needed for the 
trafficking to and association with the plasma membrane. Because of 
alternative prenylation by related geranylgeranyltransferases, the loss of 
membrane anchoring activity can be restored for N- and K-Ras, and 
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initially farnesyltransferase inhibitor treatment failed in clinical trails96. 
The increased understanding of the Ras isoform specific posttranslational 
modification process and the lack of prenylation redundancy for H-Ras 
has reignited the exploration of tipifarnib as H-Ras specific inhibitor in 
clinical trials (e.g. NCT02535650 and NCT02383927)303,304.  
 
When prenylated, Ras and Rap GTPase membrane association is regulated 
by Ras GTPase GDI-like solubilizing factor PDEδ185. Specifically, PDEδ 
activity enables Ras signaling by enriching Ras GTPase at the plasma 
membrane, whereas down-regulation of PDEδ results in a random 
distribution to all cellular membranes and thereby suppresses both wild-
type as constitutive oncogenic Ras signaling186. Deltarasin, a small 
molecule that bind to the farnesyl-binding pocket of PDEδ, disrupts the 
formation of the Ras-PDEδ complex271,272. The lead inhibitor was 
discovered through a high-throughput AlphaScreen using a farnesylated 
K-Ras4B peptide and PDEδ. Subsequent structure-guided design based on 
the crystal structure of the initial hit led to development of 
deltasarin272,273. Deltarasin is able to impair the accumulation of K-Ras at 
the plasma membrane at low micromolar concentration, thus inhibiting 
RAS signaling. Accordingly, it was shown to suppress proliferation of 
oncogenic K-Ras dependent human pancreatic ductal adenocarcinoma 
cells in vitro and in vivo.  
 
Despite the efforts put in the discovery and development of small GTPase-
modulating tool compounds, a relatively short list of compounds has been 
described, of which only a few have made it to clinical applications to 
date. Therefore, GTPase signaling inhibition efforts have resorted to 
indirect modulators, targeting Rho downstream pathways with prior 
discussed PAK and ROCK inhibitors. In similar fashion, Ras downstream 
pathways are targeted with kinase inhibitors, which are discussed in 
depth in review [207]. However, in case of mutationally activated Ras, 
the compensatory signaling cascades, such as the crosstalk between and 
the feedback loops within the MAPK and PI3K pathways, have reduced the 
overall durability and potency of such approaches, and the clinical 
outcome has often been disappointing305. Due to the better understanding 
that GTPase signaling is mediated through protein-protein interactions, 
with an essential role for regulator proteins GEFs and GAPs, opens the 
possibility to inhibit GTPase signaling by interfacial inhibitors, exemplified 
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by the natural compound Brefeldin A. However, to facilitate and enable 
larger scale screening for interfacial inhibitors, current assay methods 
needs to be adapted to be able to detect interfacial inhibition.  
 
 
 
???? ?????????
 
MgcRacGAP is a 632 amino acid long Rho GTPase GAP protein with three 
well-defined domains; a N-terminal coiled-coil, a mid-protein C1-domain 
and a C-terminal Rho-GAP domain (Figure 7). MgcRacGAP was first 
isolated through a two-hybrid cloning procedure306 using Rac2 (Q61L) as 
bait almost two decades ago307, but the target for its GAP activity is still 
controversial. After the isolation, the C-terminal GAP domain was cloned 
and it was shown that in vitro MgcRacGAP strongly stimulated GTPase 
activity of the Rho GTPases Rac1 and Cdc42, but was almost inactive 
towards RhoA307. In a parallel study it was shown that MgcRacGAP was 
expressed at high levels in replicating cells, yet not expressed in 
terminally differentiated cells, which suggested that MgcRacGAP played 
role in cell division through the regulation of Rac-related process308. Of 
note, the authors also implicated that MgcRacGAP could play a role in 
other processes regulated by Rac, such as tumor cell invasion and 
metastasis. A third study confirmed that the MgcRacGAP GAP domain was 
more active towards Rac and Cdc42 than towards RhoA in vitro309, 
however, at the same time also demonstrated using RNAi that only RhoA 
was required for cytokinesis, and, therefore, concluded that RhoA may be 
the critical target of MgcRacGAP in vivo309.  
 
MgcRacGAP mRNA expression levels were found to be cell cycle 
dependent, peaking at the G2/M phase229. Detailed immunohistochemical 
studies showed that MgcRacGAP colocalized with the mitotic spindle in 
metaphase, binding directly to microtubules via its N-terminal coiled-coil-
like domain, transferred to the midzone in anaphase and telophase, and 
thereafter moved to the midbody in cytokinesis229. During metaphase, the 
activity of MgcRacGAP is down-regulated by PRC1, which binds to the GAP 
domain of MgcRacGAP and thereby prevents phosphorylation-mediated 
GAP activity182. At the end of anaphase, MgcRacGAP, together with Mitotic 
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Kinesin-Like Protein 1 (MKLP1) form the centralspindlin, an evolutionarily 
conserved hetero-tetrameric complex, and accumulates at the cell 
equator on the overlapping antiparallel microtubules310. In telophase, 
Aurora B kinase phosphorylates MKLP1311, whereas MgcRacGAP is 
phosphorylated by Plk1, creating a docking site for the RhoGEF Ect2312-
314. As a result, Ect2 localizes to the central spindle to form the 
MgcRacGAP/MKLP1/Ect2 complex that stimulates and controls the 
activation of RhoA315-317. Premature binding of Ect2 with the 
centralspindlin is prevented by CDK-1 phosphorylation of Ect2, which 
inactivates a membrane-binding motif within Ect2 and thereby inhibits the 
Ect2–MgcRacGAP interaction during metaphase315,317. At the terminal 
phase of cytokinesis, the centralspindlin complex of MgcRacGAP, which is 
membrane bound through its C1 domain, and MKLP1, which is connected 
to the microtubules, connects the plasma membrane to the intercellular 
bridge, providing the connection between the cleavage furrow and the 
mitotic spindle needed to complete the abscission318. Interestingly, while 
the interaction between MgcRacGAP and MKLP1 is evolutionarily 
conserved, the primary structure of the N-terminal region of MgcRacGAP, 
through which the binding to MKLP1 occurs, is not well conserved310. 
 
Figure 7 Schematic representation of MgcRacGAP. Visualized in the schematic 
representation of MgcRacGAP are from N-terminus to C-terminus; the coiled coil domain, the 
protein kinase C conserved region 1 (C1, also known as cysteine-rich zinc-finger domain), and 
Rho-GAP domain, with in subscript the corresponding regions by amino acid numbering. 
MgcRacGAP interacts through its N-terminal domain with Mitotic Kinesin-Like Protein 1 (MKLP1) 
and Ect2, and through it’s C-terminal domain with Rho GTPases as well as protein regulator of 
cytokinesis 1 (PRC1). The red lines correspond with the two Polo-like kinase 1 (Plk1) 
phosphorylation sites (Ser157 and Ser164). 
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Cytokinesis is a well-studied process and the role of Ect2’s GEF activity in 
activating RhoA at the equatorial cortex is well established319,320. The 
detailed functional role of MgcRacGAP, however, is not yet fully 
resolved321-323. The relevant target GTPase in cytokinesis, as well as its 
GAP activity as such, is being debated.  
 
First, the controversy between the in vivo and in vitro data; early RNAi 
results obtained with C. elegans demonstrated that RhoA, in contradiction 
to Rac1 or Cdc42, was required for cytokinesis, and thus RhoA had to be 
the in vivo target of MgcRacGAP’s GAP activity309. In agreement with this 
hypothesis were the results obtained with Xenopus embryos showing that 
the GAP activity of MgcRacGAP was needed to inactivate RhoA creating a 
“GTPase flux,” the rapid cycling of RhoA between the GTP- and GDP-
bound forms322. Other studies suggest that MgcRacGAP’s GAP activity 
contributes to GEF activation, and thereby indirectly contribute to 
activation of RhoA324,325. However, numerous studies have demonstrated 
that in vitro MgcRacGAP has little to no GAP activity towards 
RhoA307,309,326,327, and these results are consistent with observations in C. 
elegans and HeLa cells, suggesting that MgcRacGAP’s GAP activity is 
directed to Rac1 or Cdc42321,326,328. The observation that MgcRacGAP 
colocalized with Aurora B and RhoA, but not Rac1 or Cdc42, seemed to 
shed light to the matter, as it was reported that Aurora B phosphorylation 
of MgcRacGAP serine residue 387 converted latent GAP activity toward 
RhoA to active in vitro329. However, recent studies have shown that GAP 
activity was not converted by phosphorylation at serine 387326,330. 
Instead, phosphorylation at serine 387 was demonstrated to cause a GAP 
dead protein330. Strengthening the hypothesis that Rac1 is the relevant 
target GTPase and not RhoA is the recent identification of Trio as a mitotic 
GEF of Rac1, counteracting MgcRacGAP’s function in cytokinesis331.  
 
Second, in contradiction to the many studies showing that MgcRacGAP is 
essential for cytokinesis, two studies have reported that, in Drosophila 
neuroblasts and chicken B cells, MgcRacGAP’s GAP activity is not required 
at all for cell division323,332. However, these two models systems are used 
to study asymmetric cell division and the development of non-adherent B 
cells, respectively, whereas previous results have been obtained with 
adherent mammalian cell lines undergoing symmetrical cell division.  
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Soon after the discovery of MgcRacGAP it was suggested that, besides 
having function in cytokinesis, MgcRacGAP could play a role in other 
processes regulated by GTPases and the link was made to Rac-mediated 
tumor cell invasion and metastasis308. A recent study focusing on the Rho 
GTPase signaling transcriptome revealed high RNA expression of several 
RhoGAP genes in basal-like breast cancer tumors333. Further examination 
on the role of several RhoGAP, including MgcRacGAP, in promoting 
oncogenesis led the authors to propose that RhoGAPs can act as 
oncogenes in cancer. Indeed, many other papers have shown that high 
MgcRacGAP mRNA expression is not only associated with poor disease-
free survival, it also has a prognostic significance in numerous types of 
cancers, including breast cancer334-336, as well as colorectal cancer337,338, 
hepatocellular carcinoma339, gastric cancer340, non-small cell lung 
cancer341, melanoma342, squamous cell carcinomas343, and uterine 
carcinosarcoma344. Likewise, the expression of the other complex 
members MKLP1 and Ect2 has been demonstrated to be upregulated in 
cancer, and the occurrence of relapses correlates with upregulation in 
several human malignancies including colorectal, ovarian, pancreatic, and 
non-small cell lung cancer as well as hepatocellular carcinoma and 
glioblastomas222,226,228,345-351. However, it is poorly understood how and if 
the complex, or its individual components, contribute to the malignancy. 
 
Several mechanisms have been brought forward to how McgRacGAP, 
MKLP1 and Ect2 could contribute to malignancy. In both cancer and 
development, when the MgcRacGAP/MKLP1/Ect2 complex proteins are 
expressed at high levels, their functions have been linked to controlling 
polarity352, and driving epithelial-to-mesenchymal transition353. According 
to some recent reports, MgcRacGAP is localized at cell junctions of 
cultured epithelial cells and locally regulates the activity of Rac1175,354,355. 
However, there are controversies on the precise subcellular location and 
role of MgcRacGAP; it was shown that MgcRacGAP, together with MKLP1, 
regulates Rho signaling at the adherens junctions of interphase epithelial 
cells354, whereas another study demonstrated that MgcRacGAP specifically 
colocalizes at the tight junctions while Ect2 is distributed heterogeneously 
at the adherens junctions355. A third study showed that the 
phosphorylation of MgcRacGAP by Akt on threonine residue 249 results in 
the recruitment of MgcRacGAP to invasive pseudopods, where it locally 
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suppresses the activity of Rac1 resulting in increased activity of RhoA, 
promoting invasive migration in a RhoA dependent manner175.  
 
MgcRacGAP, together with Ect2, Rac1 and Cdc42, is required for 
centromere maintenance by stabilizing newly incorporated CENP-A during 
G1 phase356. CENP-A is an essential histone H3 variant located in the 
centromeres, where it directs kinetochore assembly during mitosis. Thus, 
improper functioning of MgcRacGAP could lead to inappropriate CENP-A 
incorporation needed for successful chromosome segregation and, 
therefore, result in genomic instability. Moreover, the MgcRacGAP/MKLP1/ 
Ect2 complex is required for initiation and progression of cytokinesis, but 
needs to be inactivated to complete it. Sustained Aurora B activity was 
demonstrated to lead to persistent MKLP1 phosphorylation, delaying 
abscission357. Accordingly, overexpression of the centralspindlin could lead 
to an increased frequency of cell division failure, resulting in aneuploidy 
that is presumed to be an early step in cancer formation229.  
 
After cytokinesis, the complex becomes part of the midbody, which 
remains with the daughter cell carrying the older centrosome358. Midbody 
loss is associated with stem-cell differentiation, whereas the gain of it 
leads to reprogramming to induced pluripotent stem cells and increased 
tumor characteristics of cancer cells in vitro358. Overexpression, as such, 
is expected to lead to midbody enrichment and increasing tumorigenicity 
of cancer cells. Additionally, MgcRacGAP was reported to be essential for 
the nuclear translocation of STAT factors, including the oncoprotein 
STAT3, which is well known to regulate cancer drug resistance and 
stemness359-361. In these studies is described the seemingly contradictory 
interaction between MgcRacGAP, GTP-bound Rac1 and STAT family 
members 3 and 5A, implicating that the MgcRacGAP/Rac-GTP complex 
functions both as a mediator of STAT tyrosine phosphorylation and as a 
chaperone for nuclear translocation of STAT transcription factors361.  
 
Taken together, it is clear that MgcRacGAP is involved in a multitude of 
different processes that, when deregulated, all could contribute to human 
oncogenesis, such as sustained proliferation, promoting genetic 
instability, activating invasion and metastasis362. Like in cytokinesis, the 
role of MgcRacGAP in the processes related to malignancy is under 
debate. The conflicting results on the role of MgcRacGAP, and its GAP 
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activity, could very well arise from the cellular context326,363. However, it 
was shown that experiments which manipulate a single protein, e.g. by 
overexpression of an exogenous Rho GTPase, did not only affect the 
endogenous target protein, but affected the levels and activity of other 
Rho GTPases due to competition for binding364. Therefore, it should also 
be considered that the varying results are likely an outcome of studying a 
highly temporally controlled process by using molecular biology tools that 
are not temporally controlled nor can easily be dosed.  
 
In summary, research of the previous decades has shown that GTPases 
and their regulators function as essential signaling nodes for many pivotal 
regulatory pathways. These pathways form a highly integrated signaling 
network of regulatory events controlling normal cell physiology as well as 
aberrant function. Small molecule modulators of GTPase activity would be 
highly valuable to further delineate these pathways, but very few effective 
probes of this kind currently exist. To address this gap, we have focused 
on discovering different small GTPase-modulating probes through 
different screening approaches.  ?
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3. Aims of the study 
 
The overall aim of this doctoral study was to identify and utilize new small 
molecule modulators of GTPase activity, focusing on the previously 
undrugged GAP proteins, and thereby improve the understanding of the 
Ras superfamily of small GTPases and their regulators.  
 
The specific aims were  
 
1. Develop small molecule inhibitors of MgcRacGAP that can be used 
to study MgcRacGAP and evaluate it as a potential therapeutic 
target. 
 
2. Study the role of MgcRacGAP as mediator of phosphorylation and 
chaperone for nuclear translocation of STAT proteins. 
 
3. Develop a high throughput screening (HTS) compatible method 
to allow identification and characterization of novel small molecule 
inhibitors of the Ras GTPase cycle.  
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4. Material and methods 
 
The materials and methods used in the presented thesis have been 
described in great detail in the original publications, but a brief general 
description of the techniques used are also described here. The following 
tables summarize the fundamental experimental procedures, reagents 
and cell culture details.  
 
 
Table 2 List of methods used during this thesis 
Method Study 
Protein expression and purification I 
Biochemical GTPase assays I, III 
Synthesis of MINC1 I 
HTS data analysis I, III 
Protein-protein interaction dynamics I 
Cell culture and transfection methods I, II, III 
Cytotoxicity and cell proliferation assays I, III 
Active GTPase pull-down assay I, III 
Immunofluorescence analysis I, II 
Gel electrophoresis and western blot analysis I, II, III 
Luciferase reporter assays II 
Small molecule library screening I, III 
 
Table 3 List of reagents and compounds used during this thesis 
Reagents and compounds Study 
Small molecule compound libraries I, III, 
Small interference RNA I, II 
MINC1 (CID 744230)  I, II 
Stattic (CID 2779853; Tocris Bioscience, 2798)  II 
Ruxolitinib (CID 25126798; ChemiTek, CT-INCB) II 
Interleukin-6  (AH Diagnostics 14-8069-62 ) II 
Interferon-α (Immuno diagnostic Oy, 11350-1) II 
pGL4.47[luc2P/SIE/Hygro] (Promega) II 
pGL4[Luc2P/STAT5/Hygro] (Promega) II 
pBABEpuro MgcRacGAP I 
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Protein expression vectors (Table 4) were constructed by amplifying the 
desired part of the DNA by polymerase chain reaction (PCR) procedure, 
adding EcoRI and XhoI restriction enzyme recognition sites to both ends 
of the amplified DNA. Subsequently, the DNA was ligated between the 
EcoRI and XhoI restriction sites of pGEX-4T-1 (GE Healthcare). The BCR 
and p50RhoGAP GAP domain expression vectors were analogous to 
constructs that have been described previously365. The human Rho 
GTPase fast-cycling variants were produced by PCR-based Phusion Site-
Directed Mutagenesis (Thermo Scientific) and subcloned into the bacterial 
expression vector pGEX-4T-1. All DNA constructs were confirmed by DNA 
sequencing. 
  
Recombinant proteins were expressed and purified as described366. In 
short, DH5α or BL-21 bacterial cultures were grown up to 1 liter and 
subsequently induced with a final concentration of 100 µM isopropyl β-D-
1-thiogalactopyranoside (IPTG) to express the fusion proteins. After an 
overnight induction at room temperature, the bacterial pellet was 
resuspended in ice-cold lysis buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 
1 mM MgCl2, 1% Triton X-100, 1 mM DTT, 1 mM PMSF, 10 µM GDP), 
sonicated, cleared by centrifugation and soluble fusion proteins were 
captured with glutathione-sepharose or Ni-NTA-sepharose. Protein-bound 
beads were washed two times with lysis buffer, followed by two times 
with wash buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 1 mM MgCl2, 
1 mM DTT, 10 µM GDP). Wash and elution buffers for the GAP domain 
constructs lacked MgCl2 and GDP. The GST fusion proteins were eluted 
from the beads with elution buffer (10 mM Glutathione, 50 mM Tris 
pH 8.0, 1 mM MgCl2), whereas 6xHis fusion proteins were further washed 
with 1 mM and 5 mM imidazole supplemented wash buffer and 
subsequently eluted with 150 mM NaCl, 20 mM HEPES pH 7.5 and 80 mM 
imidazole. Protein concentrations were determined using Bradford protein 
assays367, pooled when necessary and immediately snap frozen and 
stored at -80°C. SDS-PAGE and Coomassie Blue staining were used to 
analyze protein purities. 
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In short, all GAP assays, except for the GTP hydrolysis by wild type Rac1, 
were performed in a buffer containing 15 mM HEPES (pH 7.5), 20 mM 
NaCl, 1 mM EGTA, 0.02% Tween 20, 0.1 mg/mL bovine serum albumin, 
2% dimethyl sulfoxide (DMSO) and 150 μM GTP at room temperature for 
2 h. After optimization, the assays were carried out using 600 nM Rac1 
(F28L) and 2 nM MgcRacGAP in the primary and orthogonal screen, which 
was substituted for either 200 nM BCR or 10-50 nM p50RhoGAP 
(depending on the batch) in the counter screen assays. To mimic GAP 
activity inhibition, GAPs were omitted from the assay mix. The amount of 
hydrolysis could effectively be determined by measuring both GDP and 
inorganic phosphate, using the ADP Hunter Plus assay kit (primary 
screen) and malachite green assay (orthogonal screen), respectively. A 
prototype kit of the now-published GTPase/GAP/GEF-Glo Bioluminescent 
Assay System was used to measure GTP hydrolysis by wild type Rac1368.  
 
 
Table 4 Recombinant proteins. Proteins of which the NCBI accession is marked with asterisk 
have a mutation inserted in the original NCBI reference sequence. The mutation is given in the 
preceding column with the protein name. All proteins except for those referenced have been 
constructed for the work described in this thesis. DH5α or BL-21 bacterial strains were used to 
express the recombinant proteins. PBD, p21 binding domain; RBD, Ras binding domain. 
Protein NCBI accession Vector Study 
BCR 1010-1271 NP_004318 pGEX-4T-1 I 
Cdc42 F28L *NP_001034891 pGEX-4T-1 Unpubl. 
Ect2 415-771 NP_001245245 pGEX-4T-1 III 
MgcRacGAP 345-618 NP_001119575 pGEX-4T-1 I 
p50RhoGAP 205-439 NP_001139374 pGEX-4T-1 I 
PAK1 PBD 72-132369 NP_001122092 pGEX-4T-1 I 
Rac1369 NP_008839 pProEx HTa I 
Rac1 F28L *NP_008839 pGEX-4T-1 I 
Rac1 Q61L369 *NP_008839 pProEx HTa I 
Rac3 F28L *NP_005043 pGEX-4T-1 Unpubl. 
Raf-1 RBD 1-149370 NP_002871 pGEX-2T  III 
RhoA369 NP_001655 pGEX-4T-1 III 
RhoA F30L *NP_001655 pGEX-4T-1 Unpubl. 
RhoG F28L *NP_001656 pGEX-4T-1 Unpubl. 
K-Ras 2-189371 NP_203524 pQE-A1 III 
H-Ras 2-189372 NP_005334 pQE-A1 III 
Sos 564-1049373 NP_005624 pET28 III 
p120GAP 714-1047374 NP_002881 pGEX-4T-1 III 
NF1 1198-1530375 NP_001035957 pGEX-4T-1 III 
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The GTPase nucleotide exchange assays were performed in a buffer 
containing 50 mM Tris (pH 8.0), 10 mM MgCl2, 3 mg/mL Triton-X 100 and 
0.1 mg/mL γ-globulins376. Equal molarities of GTPase/ GEF (200 nM for 
Ras and Sos, 500 nM for RhoA and Ect2) were incubated with 10 nM 
Eu3+-GTP and 22 µM Quench II371. The competitive GTP detection assays 
were conducted in a buffer composed of 20 mM HEPES (pH 7.5), 1 mM 
NaCl, 1 mM MgCl2, 0.01% (w/v) Triton-X 100 and 0.005% (w/v) γ-
globulins. GTP hydrolysis was facilitated by 500 nM GTPase, 300 nM GEF, 
900 nM GAP, 700 nM GTP, 350 nM GDP, 7.5 nM Eu3+-GTP, 12 nM 2A4GTP 
and 2.5 µM Quench III. The primary screening was conducted with H-Ras, 
RasGAP p120RasGAP and RasGEF Sos, but was substituted in the follow-
up screens by K-Ras and RhoA (with Ect2 as GEF). After 20 min 
incubation, the time-resolved luminescence (TRL) signals were monitored. 
 
 
 
?????????? ??????????????????????????
 
For the small molecule library screening, compounds were transferred by 
Echo acoustic dispensers from stock solutions plates into the appropriate 
destination assay plates for single dose testing. The 20 480 screened 
small molecule compounds for the MgcRacGAP inhibitor study were from a 
chemical diversity collection from ChemDiv, whereas 1 280 compounds 
from a ChemBridge chemical diversity collection were used for the Ras 
inhibitor screening assay. Dose response testing at the concentration 
range of 0.1-100 µM was done for compounds identified in single dose 
screening using the primary assay conditions as well as homologue 
proteins. Analogous to the MgcRacGAP inhibitor study at FIMM, an 
additional 342 046 compounds from the NIH Molecular Libraries Small 
Molecule Repository were screened at Southern Research Institute 
(Birmingham, AL, USA; See PubChem AID 624330 for complete protocol).  
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MINC1 has been re-synthesized by Annika Fagerholm in the group of Ari 
Koskinen at the Aalto University. See Figure 8 for the synthesis of MINC1. 
A short list of analog compounds have been synthesized to obtain 
structure-activity relationship (SAR) data for further development of 
potent inhibitors analogs as well as to be used to study the function of 
MgcRacGAP in cells. 
 
 
 
??????????????????????
 
Positive and negative control samples were used to determine the Z’-
factor values for each HTS assay plate, whereafter plates with Z’-factor 
values lower than 0.5 were excluded from further analysis377. Next, the 
controls were normalized as 100% and 0% inhibition and used to 
calculate the normalized inhibition for each compound. The cutoff values 
for each assay are given in Table 5. GraphPad Prism was used to fit the 
four-parameter dose-response curves constrained between 0% inhibition 
at the bottom and 100% inhibition at the top of the curve.  
 
 
Table 5 Overview of cutoff values used for the HTS assays. SD, standard deviation. 
Assay Threshold Study 
Primary GAP assay ≥3 SD above mean I 
Orthogonal assay ≥30% I 
Counter screen assay ≥50% MgcRacGAP 
≤15% BCR GAP 
I 
GTP hydrolysis assay ≥25% inhibition III 
GTP association assay ≥25% inhibition III 
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Figure 8 Synthesis of MINC1 analogs, general conditions and results. A) Summary of MINC1 
and analog synthesis. X represents an oxygen, sulfur or nitrogen atom and n represents 1 or 2 
carbon atoms, specified in lower table. Nd, not determined. B) In the previous conditions, entries 3 
and 5 did not yield any product. Therefore, a different method to synthesize those was needed. 
The salt formulations made the molecules more soluble. (Image kindly provided by Annika 
Fagerholm.) 
NC
CN
X
N
X
N
Cu(OAc)2*H2O, 
PhCl, 120oC, on
n=1-2
n=1-2
naphtalene-2,6-
dicarbonitrile
NC
X
N n=1-2
product intermediate
 
 
 
 
 
 
 
aGeneral conditions: naphthalene-2,6-dicarbonitrile 1.4 mmol, 100 mol %, chlorobenzene (0.55 mL), Cu(OAc)2 10 mol 
%, nucleophile for example 3-aminopropanol 800 mol %, reaction was stirred at 120oC overnight. 
 
 
Entrya nucleophile 
product 
Intermediate (%) Yield (%) 
X n 
1 2-aminoethanol O 1 37 15 
2 2-aminoethanethiol S 1 Nd 59 
3 Ethylene diamine N 1 Nd Nd 
4 3-aminopropanol O 2 Nd 44 
5 propane-1,3-diamine N 2 Nd  Nd  
OH
O
HO
O
H
N
N
N
H
N
2HCl
i) H2NC2H4NH2?HCl,  
H2NC2H4NH2, 
p-TsOH?H2O,
ethylene glygol, 
190oC
ii) HCl, MeOH 
38%
OH
O
N
H
N
HCl
ii) HCl, MeOH  
13%
i) H2NC2H4NH2?HCl,  
H2NC2H4NH2, 
p-TsOH?H2O,
ethylene glygol, 
190oC, 23%
OH
O
HO
O
2HCl
i) H2NC3H6NH2?HCl,  
H2NC3H6NH2, 
p-TsOH?H2O,
ethylene glygol, 
190oC
ii) HCl, MeOH 
62%
H
N
N
N
H
N
B
A
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Protein-protein interaction between MgcRacGAP and Rac1 Q61L was 
confirmed with a pull-down assay using immobilized GST-MgcRacGAP and 
soluble 6xHis-Rac1 (Q61L). In brief, 25 µM of Rac1 (Q61L) was incubated 
with equal molar glutathione sepharose bead-bound MgcRacGAP for 2 h at 
4°C, using a buffer containing 15 mM HEPES (pH 7.5), 20 mM NaCl, 1 mM 
EGTA, 0.02% Tween 20, 0.1 mg/mL bovine serum albumin. The same 
buffer with 0.1% Tween 20 was used to wash the beads three times and 
subsequently was washed an additional three times with reaction buffer 
(containing 0.02% Tween 20). Equal volume of 2x Laemmli buffer was 
added and the sample was processed as a western blot sample (described 
in section 4.11 of this thesis) and immunoblotted for Rac1. 
 
Dissociation of 6xHis-Rac1 (Q61L) from immobilized GST-MgcRacGAP was 
analyzed by bio-layer interferometry using an Octet Red 384 (ForteBio). 
MgcRacGAP was immobilized by dipping anti-GST probes in 2 µM GST-
MgcRacGAP, 1x phosphate-buffered saline (PBS) solution with 2% DMSO. 
Rac1 (Q61L) was bound to MgcRacGAP by transferring the probes to 
3.5 µM 6xHis-Rac1 (Q61L), 1x PBS solution with 12.5-50 μM MINC1 or 
2% DMSO. In the last step, the probes were transferred to a 1x PBS 
solution with 12.5-50 μM MINC1 or 2% DMSO to determine the 
dissociation of Rac1 (Q61L) from MgcRacGAP. 
 
 
 
?????????????????????????????????? ???????
 
The cell lines used in the studies throughout this thesis were cultured in 
specified growth medium (Table 6) supplemented with 100 units/mL 
penicillin and 100 µg/mL streptomycin. When indicated by provider, 
selection antibiotics were used in expansion stage as well. Subsequently, 
the cells were frozen down in small aliquots. This allowed us to perform 
and repeat all experiments with cells in the same passage number.  
 
We used different transfection methods to specifically enhance or inhibit 
gene expression. In brief, to overexpress protein or to introduce a 
reporter plasmid, cells were transiently transfected with plasmid DNA 
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using either Lipofectamine 2000 or FuGENE HD. Gene silencing was 
achieved with small interference RNA, which were introduced into the 
cells with Lipofectamine 2000 for bulk transfections or RNAiMAX in case of 
multi-well screening. Details on specific cellular assays, e.g. cell cycle 
synchronization, cellular movement and wound healing assays as well as 
the cell cycle reporter assay, are described in study I.  
 
Table 6 Overview of the cell lines and culture conditions used in the studies for the 
presented thesis. DMEM; Dulbecco's Modified Eagle Medium, EMEM; Eagle's Minimum Essential 
Medium, v/v; volume/volume, FBS; fetal bovine serum, and RPMI; Roswell Park Memorial 
Institute. 
Cell line Study 
HeLa (ATCC, CCL-2) 
Cervical epitheloid carcinoma 
EMEM, 10% (v/v) FBS 
I, II 
MDA-MB-231 (ATCC, HTB-26) 
Mammary gland epithelial adenocarcinoma 
DMEM, 10% (v/v) FBS, 10 µg/mL insulin 
I 
A549 (ATCC, CCL-185) 
Alveolar basal epithelial adenocarcinoma  
DMEM, 10% (v/v) FBS 
I, III 
RWPE-1 (ATCC, CRL-11609) 
HPV-18 immortalized prostate  
RPMI 1640, 10% (v/v) FBS 
I 
HEK293 GloResponse SIE Luc2P Hygro cells (Promega) 
Embryonic kidney 
DMEM, 10% (v/v) FBS, 200 µg/mL Hygromycin B 
II 
HEK293 (ATCC, CRL-1573) 
Embryonic kidney  
DMEM, 10% (v/v) FBS 
II 
NCI-H460 (ATCC, HTB-177) 
Large cell lung carcinoma  
RPMI 1640, 10% (v/v) FBS 
III 
NCI-H292 (ATCC, CRL-1848) 
Bronchial epithelial carcinoma  
RPMI 1640, 10% (v/v) FBS 
III 
?
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Cells were exposed to hit compounds to identify those compounds that 
were directly toxic to cells. While small details varied from assay to assay, 
in essence all compounds were tested in dose response (0.1 - 100 µM), 
using vehicle (DMSO or water) and 20 μM benzethonium chloride as 
negative and positive controls for cell death, respectively. To determine 
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toxicity, the cell culture growth medium was supplemented with CellTox-
Green reagent according to manufacturer’s recommendations. CellTox-
Green is stable at 37°C for a prolonged period of time, which allows not 
only to obtain end-point data, but also kinetic data when followed by live 
cell imaging using an IncuCyte FLR microscope (Essen Bioscience). Cell 
proliferation was determined by either phase contrast confluency or 
CellTiter-Glo Luminescent Cell Viability Assay (used according to 
manufacturer’s recommendations). 
 
 
 
??????????????????????????????????
 
To assess whether a hit compound had an effect on the GTPase activation 
status, GTP-GTPase levels were determined by pull-down assay using 
immobilized PAK1 PBD and Raf1 RBD for Rac1 and Ras, respectively. In 
brief, cells were treated with either compound or vehicle and after an 
incubation period lysed in lysis buffer (20 mM HEPES (pH 7.5), 150 mM 
NaCl, 1% Triton, 1 mM MgCl2) supplemented with protease inhibitor 
cocktail (Millipore #539134). The concentration-equalized lysates were 
incubated with appropriate immobilized protein binding domain before 
being processed analogous to a western blot sample (described in section 
4.11 this thesis).  
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For immunofluorescence (IF) analysis, cells were fixed with ice-cold 
methanol or 4% formaldehyde in 1x PBS and subsequently blocked with 
5% (weight/volume; w/v) bovine serum albumin (BSA) in 1x PBS to 
prevent unspecific binding of the antibodies. In case of formaldehyde 
fixation, the blocking buffer was supplemented with 0.2% (w/v) Triton X-
100 and 0.05% (w/v) Tween 20 to permeabilize the cells. Primary and 
secondary antibodies (see Table 7) were diluted in same solutions, unless 
stated otherwise by the manufactures. After each antibody 
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Table 7 Antibodies used in this thesis. IF, immunofluorescence; n.a., not applicable; WB, 
western blot. 
Primary antibodies 
Antibody Organism Method Dilution Source Study 
α-tubulin  mouse WB 
IF 
1:500 
1:500 
Sigma-Aldrich 
(T9026) 
I, II 
MgcRacGAP  goat IF 1:300 Abcam  
(ab2270) 
I 
MgcRacGAP mouse WB 1:500 Santa Cruz  
(166477) 
II 
Rac1  
 
mouse WB 1:500 BD Transduction 
Labs (610650) 
I 
STAT3 mouse WB 
IF 
1:1 000 
1:1 000 
Cell Signaling 
(9139) 
II 
phospho-STAT3 
Y705 
rabbit WB 
IF 
1:500 
1:1 000 
Cell Signaling 
(9131) 
II 
Pan-Ras mouse WB 1:500 Merck Millipore 
(OP40) 
III 
phospho-Erk1/2 
Thr202/Tyr204 
mouse WB 1:500 Cell Signaling 
(9106) 
III 
Erk1/2 rabbit WB 1:1 000 Santa Cruz 
(sc-94) 
III 
phospho-Akt 
Ser473 
rabbit WB 1:500 Cell Signaling 
(4060) 
III 
Akt mouse WB 1:1 000 Cell Signaling 
(2920) 
III 
phospho-Mek1/2 
Ser217/221 
rabbit WB 1:500 Cell Signaling 
(9154) 
III 
Mek1/2 mouse WB 1:1 000 Cell Signaling 
(4694) 
III 
 
Secondary antibodies 
Antibody Organism Method Dilution Source Study 
anti-mouse 
IRDye 680 
goat WB 1:15 000 Li-cor Odyssey 
(926-32220) 
I, III, 
II 
anti-rabbit 
IRDye 800 
goat WB 1:15 000 Li-cor Odyssey 
(926-32211) 
I, III, 
II 
anti-mouse 
Alexa Fluor 488  
 
goat IF 1:400 Thermo Fisher 
Scientific 
(A11017) 
I, II 
anti-rabbit Alexa 
Fluor 555  
 
donkey IF 1:400 Thermo Fisher 
Scientific  
(A-31572) 
II 
anti-goat Alexa 
Fluor 647  
 
donkey IF 1:400 Thermo Fisher 
Scientific  
(A-21447) 
I 
 
Dyes 
Antibody Organism Method Dilution Source Study 
Hoechst 33342  n.a. IF 1:1 000 Thermo Fisher 
Scientific (H1399) 
I, II 
Alexa-555 
Phalloidin  
n.a. IF 1:40 Thermo Fisher 
Scientific 
(A34055) 
I 
 62
incubation step, excess of antibody was removed by extensive washing 
with PBS. Coverslips were mounted with medium containing DAPI when 
appropriate. Slides were imaged using a Nikon 9i fluorescence microscope 
with 10x or 60x objective and NIS elements AR software, whereas plates 
were imaged using ScanR with 20x objective and associated software. 
Afterwards, the color balance was normalized for all images using ImageJ. 
For the quantification of MINC1’s effects on cell division arrest, eight 
randomly chosen fields per condition were manually scored for the 
number of normal (mononuclear), mitotic (rounded up), multinuclear and 
dead cells by eye. To evaluate the effect of MINC1 on STAT3 
phosphorylation, ImageJ was used to quantify the relative signal 
intensities of phospho- and total STAT3 in randomly selected images of 
different conditions. 
 
 
 
????????????????????????????? ?????????????????????
 
Protein concentrations of purified recombinant protein solutions were 
determined using the Bradford protein assay367, whereas protein 
concentrations of cell lysates were determined with DC protein assay. 
After recombinant protein solutions and concentration-equalized lysates 
were denaturized by heating for 5 min at 95°C with Laemmli buffer 
containing 0.05 mM DTT, the samples were loaded and separated on 10-
15% SDS-PAGE gel. Coomassie Blue staining was applied for the 
recombinant protein samples to analysis protein purities, whereas cell 
lysate samples were transferred to PVDF (polyvinylidene fluoride) 
membrane and stained with appropriate antibodies to semi-quantify 
protein expression using a Li-Cor Odyssey infrared imaging system. 
 
 
 
????????????????????????????????
 
The exact details of each luciferase reporter assay can be found in study 
II as well as in the literature378,379, but generally cells were plated such 
that at the day of measurement cells had reached a near-confluent state. 
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HEK293 GloResponse SIE Luc2P Hygro (HEK293 SIE-Luc) cells, which 
stably express a STAT3 firefly luciferase reporter, were used for the 
majority of experiments. In other cases, reporter plasmids were 
transiently transfected into HEK293 or HeLa cells using either 
Lipofectamine 2000 or FuGENE HD. If required, cells were starved using 
growth medium containing 0.5% (v/v) FBS 6 h before measurement 
and/or stimulated with appropriate cytokine or vehicle 3 h before 
measurement. Luciferase activity was measured using One-Glo luciferase 
detection reagent (Promega) according to the manufacturer’s 
recommendations.  
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5. Results and discussion 
???????? ????????????????????????????
 
????????????????????????? ???????????????????????????????
To address the lack of chemical tools to probe MgcRacGAP’s function, we 
set out to identify an MgcRacGAP inhibitor that could help to provide 
insight into the biological role of MgcRacGAP. The first challenge was to 
overcome the very high affinity of small GTP-binding proteins for the 
nucleotide12. Without a GEF in the assay solution, the nucleotide 
exchange step will be the rate-limiting step restricting a biochemical 
assay using wild type small GTPases to a near-single turnover assay 
(Figure 9A). Previously, it was shown that the GDP dissociation rate of 
Gαi1 GTPase subunit of heterotrimeric G-proteins increased if a mutation 
was introduced in the conserved TCAT loop380. Using this mutant protein 
and the GAP RGS4 (Regulators of G-protein Signaling 4), multiple rounds 
of turnover of GTP to GDP were measured. In similar fashion, for the so-
called fast-cycling mutant small GTPase proteins, which were shown to 
display a lowered nucleotide affinity, the GDP dissociates from the GTPase 
in the absence of a GEF381. In a GTP-rich environment, this results in a 
continuous GTPase cycle with the GTP hydrolysis step as the rate-limiting 
factor, making it possible to measure GAP activity alterations (Figure 9B). 
Using fast-cycling mutants of several Rho GTPases, we determined for 
each the GAP-stimulated GTPase activity with different GAPs and 
established what GAP concentrations to use to remain in linear response 
range (Figure 10, unpublished). Consistent with previous studies 
suggesting that MgcRacGAP is a GTPase activating protein for Rac1 and 
not RhoA326, MgcRacGAP did not exhibit GAP activity toward RhoA. In 
case of our primary GTPase and GAP pair, Rac1 and MgcRacGAP, using 
the fast-cycling protein allowed for a three- to fourfold signal window 
between intrinsic and GAP-stimulated GTPase activities, while remaining 
in a linear response range of GAP concentrations (I; Figure 1C). 
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Figure 9 Design of an HTS-compatible assay using fast cycling GTPase mutants to 
measure the biochemical activity of GAPs. A) Wild type GTPase cycles between GDP- and 
GTP-bound forms. Due to a very high affinity towards the guanine nucleotides, the nucleotide 
exchange step is highly rate limiting (red arrow). B) Fast-cycling mutant GTPase (GTPase*) exhibit 
reduced affinity for nucleotide, which results in a higher rate of nucleotide exchange compared to 
wild type GTPase. With an excess of GTP, this system will continuously cycle with the GTP 
hydrolysis step as rate limiting factor (red arrow). In this thesis fast-cycling mutant GTPases Rac1 
(F28L), as well as Rac3 (F28L), Cdc42 (F28L), RhoA (F30L) and RhoG (F28L) were used in 
combination with the GAP domains of MgcRacGAP (345-618), p50RhoGAP (205-439) and BCR 
(1010-1271). 
 
The GAP-stimulated GTPase reaction can be monitored by the increase of 
inorganic phosphate as well as GDP or the decrease of GTP (Figure 9). We 
decided to monitor the production of inorganic phosphate and GDP, which 
could be measured effectively using malachite green and the ADP Hunter 
Plus assay kit from DiscoveRx, respectively. In addition to detecting 
different analytes, these methods are based on different detection 
readouts (absorbance vs. fluorescence). This makes the combination of 
these assays ideal for the use of a primary and secondary orthogonal 
validation screening strategy. Since the ADP Hunter Plus assay gave 
higher and more consistent Z'-factors than the malachite green assay, we 
decided to use the ADP Hunter Plus assay as the primary detection 
method and the malachite green assay as an orthogonal validation 
method.  
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Figure 10 GAP activity is GTPase dependent. Each GAP has a different GAP activity for different 
small GTPase proteins. The response range for each GAP-GTPase pair was determined by titration. 
The GAP concentrations used in the screen were adjusted to obtain similar GAP-stimulated GTPase 
activity in all assays, yet remain in linear response range. Error bars represent SD (n=3). 
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Next, to make the MgcRacGAP-Rac1 assay HTS compatible, we optimized 
protein and GTP concentrations as well as incubation times in a 96-well 
format and subsequently miniaturized to 384- and 1536-well formats 
using automated liquid handling (I; Table 1). MgcRacGAP was omitted 
from the assay mix to mimic 100% inhibition of the GAP activity. In 
addition to omitting the GAP, including a GAP insensitive mutant like Rac1 
(Q61L) appears to an ideal negative control for the in vitro specificity 
assays. However, the GAP insensitive mutant Rac1 (Q61L) also has an 
impaired intrinsic GTPase activity. Therefore, it will be unlikely to detect 
any signal of GDP-release. 
 
 
??????????????????? ???????????????????????????????????????????
For this study we performed two high throughput screens. In-house, we 
performed a 20 480 compound screen using a chemical diversity set from 
ChemDiv. In addition, we screened 342 046 compounds from the NIH 
Molecular Libraries Small Molecule Repository chemical collection 
(PubChem AID 624330). As expected, we observed that the majority of 
the analyzed compounds showed little or no GAP inhibition. Predefined 
thresholds  (Table 5) were applied to identify active compounds eligible 
for verification by follow-up screening. In case of the screening campaign 
with NIH, a computational filter was used after the primary screen to 
reduce the number of false positive compounds by cross-referencing our 
data with data from previous NIH screens using the ADP Hunter assay. 
The implementation of the filter increased the confirmation ratio in the 
orthogonal assay from 13% in the in-house screen to 23% in the NIH 
screen.  
  
Table 8 Results identification of an MgcRacGAP inhibitor through a novel type of 
screening assay. N.a., not applicable; SRI, Southern Research Institute.   
?? ?? ????????
????????????????????????????? ??????? ????????
??? ?????????????????????????????????? ???? ??????
???????????????????????????????????????? ????? ??????
?????????????????? ?????????????????????? ??? ????
?????????????????????????????? ????? ???
????????????????? ?????????????????? ?? ?????
?????????????????????????????????????? ?? ??
????????????????????????????????????? ?? ??
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After systematically executing the primary screens and complementary 
assays (Table 8), we were able to identify and confirm two compounds 
that showed selective biochemical inhibition of MgcRacGAP in vitro. The 
first compound, which we named MINC1 (MgcRacGAP Inhibitor Compound 
1; Figure 11A), showed an MgcRacGAP-selective dose response curves 
with an half maximal inhibitory concentration (IC50) of 15±5 μM and no 
detectable activity towards BCR and p50RhoGAP (Figure 11B). When we 
analyzed the selectivity of MINC1 towards MgcRacGAP using different 
GTPases, we found that MINC1 showed selectivity towards MgcRacGAP 
and Rac1 (Figure 11C, unpublished). New structural insight into Rac1 
recognition of MgcRacGAP may explain why MINC1 is Rac1-MgcRacGAP 
specific. First, compared to other RhoGAPs, the arginine finger of 
MgcRacGAP is aligned differently382. Second, like other Rho GTPase and 
RhoGAP pairs, the surface charges are complementary; a generally 
positive charged surface area of MgcRacGAP interacts with the opposing 
largely negative charged surface of Rac1. However, because of the 
exceptional conformation of MgcRacGAP’s arginine finger, the space 
between MgcRacGAP and Rac1 at the interactive area is twice as large as 
compared to other Rho GTPase and RhoGAP pairs382. In our in silico 
modeling experiments we could not dock MINC1, or any of the other 
inhibitors, to either the surface of MgcRacGAP or Rac1. However, with this 
new knowledge of a different binding mode, it would be interesting to 
perform a docking study using both MgcRacGAP and Rac1 and test 
whether MINC1 would be able to dock to the MgcRacGAP-Rac1 specific 
groove. 
 
Using the publicly available data from PubChem, a public repository for 
biological activities of small molecules, we found that MINC1 (CID 
744230) had been included in 23 reported bioassays to date and was only 
reported active in one of these assays against an unrelated target, 
showing marginal activity. To gain more insight in the functional groups of 
MINC1, we set out to explore the structure-activity relationship of MINC1 
with MgcRacGAP-Rac1. However, no close structural analogs of MINC1 
were present in our compound collection or commercially available. 
Without knowledge about possible docking sites, rational structure-based 
compound design was not possible. Thus, we synthesized a short list of 
analogs with mostly single moiety or functional group substitutions, but 
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none of these compounds appeared to be more active in the biochemical 
screen than the lead compound (Figure 12).  
 
Figure 11 MINC1 shows selectivity for MgcRacGAP and Rac1 in vitro. A) Molecular structure 
of MINC1, CID 744230. B) Dose response analyses (0.1-100 μM) of MINC1 against MgcRacGAP 
(red), p50RhoGAP (dotted black line) and BCR GAP (solid black line) with Rac1 F28L. MINC1 
selectively inhibits MgcRacGAP IC50 15±5 μM. Error bars represent SD (n=8). C) Dose response 
analyses (0.1-100 μM) of MINC1 against Rac1 F28L (red), Rac3 F28L (dotted black line) and Cdc42 
F28L (solid black line) with MgcRacGAP. MINC1 exhibits selective inhibition for Rac1 IC50 11±5 μM. 
Error bars represent SD (n=6). 
? ?? ??????
?
??
??
??
??
???
?? ???????
???
???
???
???
??
?????????
?????????
???
? ?? ??????
?
??
??
??
??
???
?? ????????
??
???
???
???
?
?????????
?????????
??????????
?
?
?
 70
 
Figure 12 Three MINC1 analogs showed modest activity in vitro. A short list of MINC1 
structural analogs, designed to have mostly single moiety (2-5) or functional group substitutions 
(6-9), were synthesized. The compounds were tested in dose response analyses (0.1-100 μM) 
against MgcRacGAP with the primary assay using MINC1 as control (red). Analogs 2 (blue), 
6 (black) and 7 (green) showed modest activity, whereas most of the newly synthesized 
compounds displayed no activity. In addition, compound 7 (green) showed similar activity versus 
p50RhoGAP and BCR GAP. Error bars represent SD (n≥3). 
 
The second hit compound, named MINC2, exhibited selectivity for 
MgcRacGAP over BCR and p50RhoGAP, with an IC50 of 18±7 μM (I; Fig. 
3B/D). While there was no significant difference between the IC50’s in the 
initial biochemical data, subsequent cell-based assays indicated that 
MINC2 had no efficacy in cells and, therefore, we continued with MINC1 
for follow-up studies. 
 
In order to reduce the error caused by different incubation times, we 
preplated the compounds and re-dissolved these in assay buffer before 
adding the rest of the assay components. Lastly, the reaction was 
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initiated by adding GTP. We found that when GTP addition was delayed, 
and thus the proteins were given the time to pre-incubate with MINC1, 
the dose response curves shifted and the IC50 decreased almost one order 
of magnitude to 2±1 μM (Figure 13A). When we analyzed this 
phenomenon more closely, we found that the shift only occurred when 
Rac1 was included in the pre-incubation mix, while presence of 
MgcRacGAP in the mixture had no additive effect on the inhibition (Figure 
13B) nor did we observe any effects on GTP hydrolysis when MgcRacGAP 
was substituted with p50RhoGAP or left out.  
 
Next, we set out to determine whether MINC1 was able to inhibit the GAP 
function of MgcRacGAP on wild type Rac1. Up till this point all the 
biochemical assay had been performed using fast cycling mutant Rac1 
(F28L). To be able to measure GAP-stimulated GTPase activity of wild 
type Rac1, we used GTP-loaded Rac1.  We found that there was no effect 
on the GAP activity by addition of MINC1 to a single turnover assay (I; 
Fig. S1B). When we replaced the fast-cycling mutant for wild type Rac1 
protein, making the nucleotide exchange the rate-limiting factor (Figure 
9A), we did not detect any notable inhibition of MgcRacGAP-stimulated 
activity by MINC1. These data suggest that, while MINC1 acts selectively 
on the Rac1-MgcRacGAP complex, the binding to Rac1 is slow and at the 
same time the interaction with MgcRacGAP is fast.  
 
Based on these data, we hypothesized that MINC1 stabilized the Rac1-
MgcRacGAP complex and as such inhibits GAP-catalyzed GTPase activity. 
To test this hypothesis we measured the real-time protein-protein 
interaction dynamics between MgcRacGAP and Rac1 in the presence or 
absence of MINC1 by bio-layer interferometry. In case the complex was 
treated with MINC1, we observed a dose dependent decrease of 
dissociation (Figure 14).  Taken together, these data suggest that MINC1 
stabilizes the Rac1-MgcRacGAP complex rather than inhibits binding.  
 
 
?????? ??????????????????????????????????????????????????????
Previous data have shown that MgcRacGAP is required to complete 
cytokinesis, but also to play an important role in centromere 
maintenance321,326,356. We predicted that if MINC1 would work as an 
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Figure 13 MINC1 acts on the Rac1-MgcRacGAP complex through Rac1. A) Using the primary 
assay conditions, a 2 h pre-incubation of MINC1 with the proteins before GTP addition results in a 
shift of the dose response curve by almost an order of magnitude; IC50, no incubation 15±5 μM, IC50, 
incubation 2±1 μM. Error bars represent SD (n=8).  B) A 2 h pre-incubation of Rac1 with MINC1 (solid 
red line) results in the same dose response curves shift as pre-incubation of the complex with 
MINC1 (solid black line). The presence of MgcRacGAP in the mixture (dotted black line) had no 
effect on the inhibition. Inc/w, incubation with. Error bars represent SD (n=3).   
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Figure 14 MINC1 stabilizes the Rac1-MgcRacGAP complex. Real-time protein-protein 
interaction dynamics between GST-MgcRacGAP and 6xHis-Rac1 (Q61L) in the presence or absence 
of MINC1 were analyzed by bio-layer interferometry. MgcRacGAP was immobilized on an anti-GST 
probe, whereafter Rac1 (Q61L) was bound to MgcRacGAP in the presence of 12.5-50 μM MINC1 or 
2% DMSO. The dissociation of Rac1 (Q61L) from MgcRacGAP was determined in the presence of 
12.5-50 μM MINC1 or 2% DMSO. Pre-incubation of MINC1 with the complex slowed down the 
dissociation process in dose dependent matter. Error bars not presented (n=2).  
 
MgcRacGAP inhibitor in cells, it would have a significant effect on cell 
growth. Next, we proceeded to investigate whether MINC1 had an effect 
on cells by monitoring cell proliferation and cell death using live-cell 
imaging. We found that treatment with MINC1 significantly, and dose 
dependently, slowed down cell proliferation (Figure 15). The predicted 
IC50 in the cell-based assay (~20 µM) was surprisingly low, being in the 
same order of magnitude as the IC50 of the initial biochemical data 
(~15 µM). Unusual kinetic behaviors such as slow binding behavior and/or 
slow off rates have been correlated with disproportionately potent cell-
based activity383. Taken together with the observed near one-order of 
magnitude shift of the IC50 in the biochemical assay after pre-incubation, 
the potent cell-based activity strengthens the hypothesis that MINC1 
stabilizes the Rac1-MgcRacGAP complex.  
 
Cell death did not occur directly upon treatment with MINC1, but only 
with prolonged high dose-treatment of MINC1 (Figure 15). We noticed 
that MINC1-treated cells rounded up, as expected during division of 
adherent cells384, but seemingly failed to complete cell division. Prolonged 
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Figure 15 MINC1 treatment dose-dependently reduced proliferation rate of human tumor-
derived cell without causing direct toxicity. MDA-MB- 231 cells were treated with 10-80 μM 
MINC1, DMSO (black) or 20 μM benzethonium chloride (BzCl, red) and followed by live cell 
imaging for 70h for proliferation (upper panel, determined by confluency) or cell toxicity (lower 
panel, determined by fluorescence intensity). Significance was assessed at three different time 
points (12 - 36 - 60h) using two-way ANOVA followed by Dunnett's multiple comparisons test 
(confluence control DMSO and death control BzCl). *, P<0.05; **, P<0.01; ***, P<0.001, ****, 
P<0.0001; n.a. not applicable; ns; not significant.  Error bars represent SD (n=4).  
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mitotic arrest cell death is associated with apoptosis385,386. We 
investigated whether MINC1 treatment prevented the cell from entering 
mitosis (M-phase). Using both non-synchronized as well as synchronized 
cell cultures, we found that MINC1 treated cells fail to pass from G2 to M-
phase (I; Fig 5). Interestingly, cells in a non-synchronized cells culture 
did not phenotypically respond until after >3 h of MINC1 exposure, 
providing support to the slow kinetic behavior of MINC1.  
 
Despite the fact that we failed to detect changes in overall Rac1 GTP 
levels upon MINC1 treatment, which is not unexpected as Rac1 will be 
mostly GDP-bound and only locally activated, these data are in line with 
what can be expected from an MgcRacGAP inhibitor. Further research 
could utilize Förster resonance energy transfer (FRET)-based biosensor for 
GTPases, e.g. the Raichu biosensors387-389, to measure the effect of 
MINC1 on the activation of Rac1 or other GTPases with high spatial and 
temporal resolution. 
 
To obtain more insight in the cell division arrest, several different cell 
lines were treated with MINC1 for up to 48 h and fixed at different time 
points for immunofluorescence staining and image analysis. MINC1-
treated cells showed a lower endpoint confluence as their counterparts 
when plated at similar densities, consistent with the earlier observation of 
reduced proliferation, as well as considerable amount of multinucleated 
cells and round-up cells with abnormal positioning of the nuclear DNA (I; 
Fig. 6C/F). To characterize the effect of MINC1 on cell cycle progression 
and failed cytokinesis, we quantified the number of normal, mitotic, 
multinucleated and dead cells (Figure 16). We observed a peak of the 
mitotic phenotype in the first 9 h after initiation of the treatment, 
whereas the number of multinucleated cells increased continuously, 
quadrupling in 24 h.   
 
A subpopulation of the MINC1-treated cells displayed abnormal mitotic 
positioning of the nuclear DNA (I; Fig. 6D). A similar monopolar spindle 
phenotype is reported for cells depleted of Plk1390-392. Plk1 is an essential 
serine/threonine kinase in multiple early mitotic processes and directly 
regulates MgcRacGAP312-314. Moreover, inhibition of Plk1 has been 
demonstrated to induce a loss of interaction between Ect2 and 
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Figure 16 MINC1 treatment impeded the cells from progressing mitosis. A549 cells were 
treated with DMSO (0 h control) or 25 μM MINC1 and fixed at different time points. The cells were 
subsequently stained to distinguish the membrane/cytoskeleton and nucleus. Immunofluorescence 
images were quantified for the amount of normal, mitotic, multinucleated and death cells per time 
point and results were plotted as a bar graph. Error bars represent SD (n>230 cells ’24 h MINC1 
treated’ condition and n>320 all other conditions). 
MgcRacGAP in anaphase, preventing initiation of cytokinesis393. Based on 
the similarities we decided to follow-up with high-magnification imaging 
and found extensive membrane protrusions (Figure 17). Cell morphology 
is determined by the balance of Rac and Rho activity394, and these 
extensive membrane protrusions found in the MINC1-treated cells may 
suggest a loss of cortical actin rigidity that has been linked to deregulated 
Rac/Rho activity395. Additionally, using a constitutively active MgcRacGAP 
mutant it was demonstrated that inhibition of MgcRacGAP is important for 
the correct formation of the mitotic spindle during the metaphase182. 
Altogether, these data suggest that the GAP activity of MgcRacGAP plays 
an important role not only in cytokinesis, but already in mitosis and may 
be regulated by Plk1.  
 
Alternatively, the abnormal mitotic positioning of the nuclear DNA may 
result from other MINC1-induced effects on the cell division machinery 
through different targets. Like the Plk1-inhibited phenotype, the Eg5-
inhibited phenotype resembles a monopolar arrest, yet with a subtle 
morphological difference; in case of Plk1 inhibition, the chromosomes are 
unevenly spaced from the spindle pole, whereas the Eg5-inhibited 
phenotype is characterized by evenly spaced chromosomes396. In study I 
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Figure 17 Abnormal spindle morphology in the metaphase in MINC1 treated cells. 
Representative 60x immunofluorescence images of mitotic and cytokinetic HeLa cells. Cells were 
treated for 48 h with DMSO (A/C/E/G) or 25 μM MINC1 (B/D/F/H).  DNA (A/B, blue G/H) was 
visualized with Hoechst stain and α-tubulin (C/D, green G/H) and MgcRacGAP (E/F, red G/H) 
stained with antibodies. The characteristic metaphase spindles originating from opposite poles are 
lacking in MINC1 treated cells, instead they have a collapse spindle morphology (C-D, indicated by 
arrow). Rounded-up MINC1 treatment cells displayed extensive membrane protrusion (D, indicated 
by round ended arrow). Scale bar, 10 µm. 
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we reported that the chromosomes were unevenly spaced from the pole, 
similar to the Plk1-inhibited phenotype, but retrospectively it is arguable 
the chromosomes have been evenly spaced from the pole (Figure 17). 
Interestingly, a study using Tiam1-depleted cells as well as Rac1-deficient 
epithelial cells showed that these cells could escape an Eg5-induced 
mitotic arrest397. Specifically, it was shown that Tiam1-Rac signaling is 
required to antagonize the Eg5-induced forces during bipolar spindle 
assembly. With Rac1 suppression shown to be essential for cytokinesis in 
both HeLa and RatA1 cells387, and observed membrane protrusions 
suggesting a high Rac1/low RhoA activity in MINC1-treated cells, we 
hypothesize that MgcRacGAP-mediated suppression of the Rac1-PAK 
pathway may play a pivotal role in the cytokinesis. Accordingly, a recent 
study showed that depletion of Rac1 substrates PAK1/2 resulted in 
resistance to Eg5-induced mitotic arrest159. Since Tiam1 is a RhoGEF, it 
acts as an antagonist of the RhoGAP. Thus, in both the Tiam1-induced as 
well as the MgcRacGAP-inhibited situation, Rac1 will be locally activated. 
To determine whether the GEF-induced and GAP-inhibited indeed result in 
a similar phenotype, it would be interesting to test if depletion of PAK1/2 
can also rescue of MINC1-induced phenotype.   
 
 
?????? ???????????????????????????????????????????????????????????????
STAT proteins are well established for their ability to transmit specific 
signals from the plasma membrane to target genes in the nucleus, albeit 
all are activated by phosphorylation of a single tyrosine, predominantly by 
JAK family kinases398. The co-regulatory events, such as nuclear import 
as well as alternative activation pathways appear to play important roles 
in the specificity of the signal399-401.  
 
Previous studies have described results linking Rac1 to STAT3 activity. For 
example, Rac1 activation was shown to induce autocrine interleukin-6 (IL-
6) secretion stimulating STAT3 activity402. Another study showed that 
activated Rac1 could form a complex with STAT3403. Accordingly, the 
authors hypothesized that Rac1-mediated recruitment presents an 
alternative method to direct STAT3 to the kinase signaling complexes at 
the membrane. Finally, a series of studies described an interaction 
between MgcRacGAP, activated Rac1 and STAT family members 3 and 
5A359-361. Specifically, the authors proposed that MgcRacGAP/Rac-GTP 
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form a stable complex, which functions both as a mediator of STAT 
tyrosine phosphorylation as well as a chaperone for nuclear translocation 
of STAT proteins361. Despite largely complementing previously proposed 
model, the results are seemingly contradictory, as the MgcRacGAP-Rac1 
interaction will initiate MgcRacGAP-mediated GTP hydrolysis and, 
therefore, it is unlikely to have a long-lived MgcRacGAP/Rac-GTP 
complex.  
 
Since previous reports proposed that the MgcRacGAP-Rac1 complex plays 
a key role in STAT activation and nuclear translocation359-361, we decided 
to examine whether targeting the MgcRacGAP-Rac1 complex with MINC1 
could interfere with STAT3 signaling. Surprisingly, we found that 
treatment with MINC1 resulted in a dose dependent increased STAT3 
signaling for both starved and IL-6 stimulated cells (Figure 18). Previous 
results had been obtained with gene silencing by siRNA and, therefore, we 
also performed a siRNA-mediated knock down experiment. However, 
using a similar setup, we could not reproduce the previous results (Figure 
19). Instead, under these conditions we observed that MgcRacGAP 
knockdown caused an increase in STAT3 transcription activity that 
resembled those obtained with MINC1. To verify whether the results were 
applicable to other cell lines as well as different assay models, we used 
transient transfections of STAT3 and STAT5 reporter plasmids in both 
HEK293 and HeLa cells. Also in these assay systems STAT transcriptional 
activation was dose dependently stimulated by MgcRacGAP-Rac1 
inhibition (II; Fig. 1D-E). 
 
Considering the role of MgcRacGAP in the highly regulated Rac1 GDP-GTP 
cycle, inhibition of the GAP function of MgcRacGAP is expected to lead to 
increased downstream signaling activity of Rac1. This downstream 
signaling activity of Rac1 can be mimicked using constitutively active 
Rac1 and work of others has shown that active Rac1 (G12V) induces 
STAT3 phosphorylation402-404. Vice versa, we and others have shown by 
using siRNA mediated knockdown of Rac1 (II; Fig. S1) and a dominant 
negative Rac1 (T17N)403,405, respectively, that the inability of activating 
Rac1 results in the loss of STAT3 transcriptional signal. Based on these 
results we concluded that the GAP activity of MgcRacGAP controls Rac1 
stimulated STAT3 transcriptional activity. 
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Figure 18 MINC1-mediated inhibition of MgcRacGAP induces a dose dependent increase 
of STAT3 transcriptional activity. Serum starved HEK293 SIE-Luc cells were, in the presence of 
vehicle (DMSO), 10 µM Stattic406 or increasing concentrations of the MgcRacGAP inhibitor MINC1, 
induced with or without IL-6. MINC-1 treatment significantly increased the STAT3 transcriptional 
activity of IL-6 induced HEK293 SIE-Luc cells (p≤0.0001, Sidak's multiple comparisons test). Error 
bars represent SD (n=3).  
 
 
Figure 19 Increased STAT3 transcriptional activity by siRNA-mediated knockdown of 
MgcRacGAP. Gene silencing by siRNA targeting MgcRacGAP in HEK293 SIE-Luc cells showed 
activation of STAT3 for serum starved and IL-6 induced conditions. Sidak's multiple comparisons 
test was used to assess significance of the siRNA-mediated knockdown of MgcRacGAP (p≤0.01). 
Error bars represent SD (n=3). 
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To clarify the mechanism leading to STAT3 transcriptional activation, we 
decided to assess STAT3 phosphorylation status as well as cellular 
localization. We used lysates of HEK293 SIE-Luc cells and demonstrated 
that both siRNA-mediated and MINC1-mediated inactivation of 
MgcRacGAP resulted in an increase of STAT3 phosphorylation signal (II; 
Fig. 1C). Immunofluorescence image analysis of fixed HEK SIE-Luc cells 
revealed an upregulation of phospho-STAT3 signal in MINC1-treated cells 
compared to untreated counterparts, whereas no differences in total 
STAT3 were observed (Figure 20). Of note, despite the increased STAT3 
transcriptional activity measured in the preceding experiments, the 
phospho-STAT3 signal appeared to be relatively uniformly upregulated 
through the MINC1-treated cells and not localized in the nucleus as might 
be anticipated (Figure 21A-B). Subsequent analysis with IL-6 stimulated 
cells showed that inhibition of MgcRacGAP did not affect the nuclear 
translocation of phospho-STAT3 (Figure 21C-D). Similar results have 
been published, showing that dominant negative Rac1 (T17N) does not 
affect nuclear transport of STAT3405. Together with the data showing that 
activated Rac1 induced STAT3 phosphorylation402-404, we hypothesize that 
the GAP function of MgcRacGAP is required for the termination of the 
GTPase signaling, but not for nuclear translocation. 
 
Figure 20 MINC1-mediated MgcRacGAP inhibition induces tyrosine phosphorylation of 
STAT3. HEK293 SIE-Luc cells were treated for 6 h with either DMSO vehicle or 25 µM MINC1, 
fixed and immunostained with anti-STAT3 and anti-phospho-STAT3. The relative intensities of the 
STAT3 and phospho-STAT3 signals were determined from randomly selected immunofluorescence 
images and normalized for each antibody separately. Significance was assessed using Wilcoxon 
matched-pairs signed rank test. Error bars represent SD (n=8; *, P ≤ 0.05,).  
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Figure 21 Treatment with MgcRacGAP inhibitor MINC1 induces tyrosine phosphorylation 
of STAT3, but does not block nuclear translocation of tyrosine phosphorylated STAT3. 
Representative immunofluorescence images of HEK293 SIE-Luc cells that were induced with IL-6 
for 3 h (C-D) in the presence of either DMSO vehicle (A/C) or 25 µM MINC1 (B/D), were fixed and 
immunostained with Hoechst dye (1), anti-phospho-STAT3 (2) and anti-STAT3 (3). In non-IL-6 
induced cell, MINC1 treated cells showed more intense phospho-STAT3 staining than control cells, 
whereas inhibition of MgcRacGAP by MINC1 did not lead to an inhibition of nuclear translocation of 
phospho-STAT3 in IL-6 induced cells. Scale bar, 25 µm. 
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Figure 22 MINC1-induced STAT3 activation is suppressed by inhibition of JAK/STAT. 
HEK293 SIE-Luc cells were treated with different concentrations of MINC1 and subsequently 
induced with IL-6 in the presence of vehicle (DMSO), 300 nM ruxolitinib (JAK1/2 inhibitor) or 
10 µM Stattic (STAT3 inhibitor). Bonferroni post-hoc results indicated that significantly less STAT3 
activation was detected when cells were treated with ruxolitinib or Stattic (p≤0.01). Error bars 
represent SD (n=6).  
 
While STAT proteins can be activated by several different regulators, they 
are predominantly phosphorylated by JAK family kinases398. It is well-
established that STAT3 is activated by JAK family kinases upon IL-6 
stimulation407 and it has also been demonstrated that Rac1-driven STAT3 
activity is dependent on JAK2403. To further examine the role of 
MgcRacGAP in the activation of STAT3, we turned to the JAK/STAT 
signaling pathway and investigated if inhibition of JAK, with JAK1/2 
inhibitor ruxolitinib408, or STAT3, with STAT3 inhibitor Stattic406, would 
prevent MgcRacGAP inhibition-meditated STAT3 activation. We found that 
both ruxolitinib and Stattic treatment effectively blocked MINC1-mediated 
STAT3 activation, which indicates that the role of MgcRacGAP in the 
activation of STAT3 is upstream of JAKs (Figure 22).  
 
In our immortalized, non-cancerous cell model STAT3 phosphorylation 
levels were inversely correlated with cell confluency (II Fig. S2), whereas 
the opposite has been reported for cancer cell lines409-411. Moreover, 
persistent activation of STAT3 in colon cancer has been shown to be 
required for tumor growth, with inhibition ceasing cell proliferation as well 
as inducing apoptosis412,413. Based on these observations, we 
hypothesized that STAT activity is upregulated in cancer cells to evade 
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cell cycle arrest as well as gain the ability to migrate from the confluent 
site. A recent publication described a mechanism for the induction of IL-6 
production through the activation of PAR3 signaling414. PAR3 is a scaffold 
protein that binds the highly selective Rac GEF Tiam1, thereby directly 
regulating Rac1 activity415-417. Another study demonstrated that PAR3 
activates STAT3 through Rac1 and that reduced tumor-invasive and 
metastatic properties were observed if impaired PAR3 activity was 
reconstituted418. Accordingly, we examined whether MINC1-mediated 
STAT3 activation was the result of PAR3-induced IL6 production and 
subsequent activation of the IL-6 receptor (IL6R)-JAK-STAT signaling 
axis. We found that MINC1-induced STAT3 activation was impaired by the 
knockdown of PAR3, JAK2 and IL6R (Figure 23). These results place 
Rac1, and its regulation by MgcRacGAP, upstream of Par3 as been shown 
before419, and suggest that the STAT3 activation is dependent on a 
paracrine or autocrine IL-6 signaling feedback mechanism. In line with 
this hypothesis, STAT3 activation in cancer cells might be the result of a 
loss of cell-to-cell integrity, causing elevated levels of phospho-STAT3, 
which allow the cells to continuously replicate. It will be interesting to test 
whether IL-6 neutralizing antibodies can attenuate this effect uncontrolled 
proliferation.  
 
 
Figure 23 MINC1-induced STAT3 activation is dependent on a PAR3-IL6-IL6R-JAK2 
feedback loop. HEK293 SIE-Luc cells were transiently transfected with siRNA targeting PAR3, IL-
6 receptor (IL6R), JAK2, STAT3 or scramble siRNA. Subsequently the HEK293 SIE-Luc cells were 
left untreated or treated with MINC1. In the PAR3, IL6R and JAK2 KD cells MINC1 treatment 
resulted in a significant loss of STAT3 transcriptional activity in comparison to the control cells 
(p≤0.05, Dunnett’s multiple comparisons test). Bars represent the average fold change for the 
non-treated and treated siRNAs pairs. Error bars represent SD (n=3). 
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Altogether, using both small molecule inhibitors and siRNAs, we 
established that inhibition of MgcRacGAP results in the activation of 
STAT3 and subsequent transcriptional activity. We found no evidence that 
MgcRacGAP has a function in nuclear translocation of STAT proteins, 
which is in contrast with earlier proposed models, established with a 
similar model system. Our results argue for a non-direct relationship 
between Rac1 and STAT3, mediated through the PAR3-IL6-IL6R-JAK2 
signaling axis. However, direct interaction between Rac1 and STAT3 
cannot be ruled out, as work of others has demonstrated that both 
models exist and, depending on cell type, even co-exist420. With the 
growing awareness of the complexity of the highly integrated signaling 
network within cell, where small GTPases and their regulators direct and 
connect different pathways, it is not unlikely that the relationship between 
MgcRacGAP and STAT transcription factors is context-dependent and 
needs to be determined case-by-case.  
 ?
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Drug discovery efforts targeting GTPases and their regulators have been 
hampered by a lack of suitable screening methodologies. Due to the high 
enzymatic activity, kinase assay have relative low protein consumption, 
whereas GTPase assays tend to use relative high concentrations of 
protein. This is particularly the case when using insensitive fluorescence-
based methods, such as Mant421 and BODIPY422,423. Measurements have 
been limited to GTPase or GEF activity, which can be achieved with 
incorporation or displacement of a fluorescently labeled analog. On the 
other hand, filtration binding assays using radioactive H-3 or P-32 γ-
phosphate-labeled GTP are sensitive, and can be used to measure GAP 
activity as well424,425. Activity is determined by measuring either residual 
radioactive GTP or inorganic phosphate, which is hazardous and, 
therefore, relatively expensive as well as not easily adapted to high 
throughput assays. Recently developed NMR methods use safe isotopes 
like C-13 and N-15 and can be applied real-time, however, they require 
substantial amount of isotope labeled protein426. 
 
A GTP-specific Fab fragment, 2A4GTP Fab, has been described and used to 
develop a heterogeneous assay to monitor GTP hydrolysis in vitro427. The 
Fab fragment has been developed to improve the quenching resonance 
energy transfer (QRET) method376, which could only be used to monitor 
GTPase nucleotide exchange. The QRET method is based on the energy 
transfer between an Eu3+-conjugated GTP and soluble quencher (Figure 
24A). When the Eu3+-GTP molecule is sterically protected, for example by 
binding to the GTPase or 2A4GTP Fab, the quencher no longer inhibits the 
lanthanide-based resonance energy transfer, resulting in an increase of 
signal. Like most other methods that monitor GTPase nucleotide 
exchange240,428,429, the QRET method could not be used to detect GTPase-
GEF complex conformation-trapping or non-competitive interfacial 
inhibitors279. However, with the introduction of the Fab fragment, the full 
GTPase reaction can be monitored; the decrease of GTP, which as a result 
of conversion to GDP is effectively replaced by the nonhydrolyzable Eu3+-
GTP from the 2A4GTP Fab, results in an increase of signal because the 
bound 2A4GTP Fab is protected from the soluble quencher (Figure 24). 
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Figure 24 Inhibitor screening strategy using competitive 2A4GTP Fab GTP hydrolysis 
detection. A) In the presence of a relative high concentration of GTP (T1), GTP will out compete 
Eu3+-GTP for binding to the GTP-specific Fab fragment, 2A4GTP Fab. While in solution, quencher 
(Q) will prevent energy transfer to the lanthanide and inhibit the luminescence signal. When less 
GTP is present (T2), Eu3+-GTP will bind to 2A4GTP Fab and be sterically protected from the 
quencher, resulting in energy transfer and luminescence signal. B) Assay setup, where in the 
presence of GEF and GAP proteins, as well as an excess amount of GTP, GTPases will continuously 
hydrolyze GTP to GDP. C) Initially, high concentrations of GTP efficiently block Eu3+-GTP binding to 
the GTP-specific binding fragment (2A4GTP Fab). As a result, most of the Eu3+-GTP is in solution 
with the soluble quencher (Q). As long as the GTPases continuously hydrolyzes GTP to GDP, GTP is 
converted to GDP and thus the nonhydrolyzable Eu3+-GTP will replace the GTP bound to the 2A4GTP 
Fab fragment. The 2A4GTP Fab fragment bound Eu3+-GTP is protected from the soluble quencher, 
resulting in an increase in time-resolved luminescence (TRL) signal over time. The reaction can be 
monitored real-time or by a two-step protocol (for which Eu3+-GTP and quencher are added after 
incubation period).  
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Because of the heterogeneous nature of the method, the GTP hydrolysis 
assay was not suitable for HTS. To create a homogenous assay suitable 
for HTS, we first optimized the salt concentrations. Previous results 
obtained with high salt concentration suggested that salt bridge formation 
potentially interfered with GTP and 2A4GTP binding, resulting in a 
suboptimal signal427. Indeed, we determined that with low salt 
concentrations the selectivity for GTP over GDP increased by an additional 
four-fold, establishing 220-fold selectivity for GTP over GDP (III; Fig. 
1B-C and Table S-1). Next, different protein and nucleotide 
concentrations were tested to determine reproducibility as well as best 
controls (III; Fig. 1E). We mimicked 100% inhibition in the same 
manner as with the MgcRacGAP assay. However, excluding GAP from the 
reaction mixture resulted in a slightly elevated background signal 
compared to omitting either GEF or GTPase. We hypothesized that the 
GEF-facilitated dissociation of GDP enabled Ras to bind GTP and, by 
intrinsic GTP hydrolysis, subsequently converted to GDP. While this 
reaction will be significantly slower than the GAP-catalyzed reaction, we 
decided that omitting the GEF from the reaction mixture would serve as 
better positive control.  
 
 
???????????????????????????????????????????????????????????????????????
In order to compare the performance of the GTP hydrolysis assay to a 
standard association assay, we miniaturized the QRET nucleotide 
exchange method376, and subsequently assayed two identical sets of 
1 280 chemically diverse compounds. The average Z’-factors ranged from 
0.64 to 0.88. To identify active compounds eligible for verification by 
follow-up screening, we applied to both methods the same, predefined, 
thresholds (Table 5). After the first round of single dose testing, we 
identified 22 hits; eight compounds were found with both methods, nine 
exclusively with the GTPase cycling assay and five only with the 
nucleotide exchange assay (Figure 25 and III; Fig. 1F/H-I). From these 
22 compounds, ten compounds were confirmed when tested as triplicates 
(III; Table 1 and Supplementary Table S-2 and Fig. S-2). Six 
compounds were identified with both the nucleotide exchange assay and 
the GTPase cycling assay. In addition, we identified a set of four 
compounds exclusively with the GTP hydrolysis assay. In subsequent dose 
response testing, all appeared to inhibit GTPase cycling or nucleotide 
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association in a concentration dependent manner. Of note, for most of the 
hit compounds there was only limited amount of bioactivity data available 
on PubChem. While most compounds with additional public bioactivity 
data were inactive in those cases, three compounds (QT-13, QT-113 and 
QT-317) had tested active in some bioassays, but none of these 
compounds were previously presented in a context of GTPases. Based on 
a pan-assay interference compounds filter430, three compounds (QT-13, 
QT-26 and QT-113) were identified as containing substructural features 
that frequently cause false positive activity in a broad range of assays. 
 
The primary screening identified a set of five compounds that were only 
active in the nucleotide exchange assay. Since the GTPase cycling assay 
should detect both GTP hydrolysis inhibitors and nucleotide exchange 
inhibitors, we did not expect to identify such a group, unless they were 
false positive hits. Confirmatory testing showed, like expected, that none 
of these five compounds had activity in the nucleotide exchange assay.  
 
 
Figure 25 The GTPase cycling assay identifies compounds that would go undetected by 
nucleotide exchange assay screening. A total of 22 compounds were identified in the primary 
screening round; nine were exclusively detected with the GTPase cycling assay (blue circle), five 
with the nucleotide exchange assay (yellow circle) and eight were found with both methods 
(overlap; in green). When the hit compounds were retested in triplicate, 10 of the 22 compounds 
confirmed; six exhibited inhibitory activity in both assays, suggesting that they affected nucleotide 
binding or exchange, whereas four inhibited only the GTPase cycling assay, suggesting that they 
were inhibitors of GTP hydrolysis or GAP activity. 
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Figure 26 Three compounds show efficacy in cell-based assays. Three lung cancer cell lines 
dependent on the K-Ras signaling pathway were subjected to dose response treatments of QT-43 
(upper panels), QT-47 (middle panels) and QT-113 (lower panels). NCI-H292 (KRASwt) (left), A549 
(KRASG12S) (middle) and H460 (KRASQ61H) (right) were treated for 72 h, whereafter cell death 
(red) and cell survival (black) were determined by the multiplexed CellTox-Green cytotoxicity and 
CellTiter-Glo cell viability assay. Error bars represent SD (n=3).   
To address the specificity of the identified compounds, we changed 
RasGAP p120RasGAP for NF-1 in the GTP hydrolysis assay (III; Table 1). 
It has been shown that NF-1 and p120RasGAP have different kinetic and 
thermodynamic characteristics when interacting with Ras, as well as form 
strikingly different complexes with Ras201,431. Changing the GAP did not 
result in a different inhibition pattern. Therefore, we hypothesized that 
these inhibitors target either the Ras or the Ras-Sos interface. To test this 
we used the related and unrelated GTPase proteins, K-Ras and RhoA (with 
RhoGEF Ect2), respectively, in the nucleotide association assay (III; 
Table 1). The interaction between GTPase and regulators is, in the 
majority of cases, family specific. We found that with the same threshold, 
five out of six compounds inhibited also the K-Ras/Sos interaction, 
whereas Rho/Ect2 nucleotide exchange was not affected. These data 
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strengthen the hypothesis that these inhibitors target Ras or the Ras-Sos 
interface. However, since all assays have been performed with the same 
detection technique, it could be possible that the compounds interfere 
with the QRET method. Though unlikely for a lanthanide-based assay to 
cause false positive detection due to autofluorescence432, altering kinetics 
of nucleotide hydrolysis and/ or exchange could also be affected by the 
detection method. The well-established Mant-GTP assay421, commonly 
used to measure nucleotide exchange, has recently been shown to have 
effects on GTPase reaction kinetics with the Mant-moiety433. Future 
research should address the lack of orthogonal screening by testing these 
hits using the Mant-GTP assay, which should be used with caution, and/ 
or the new GTPase/GAP/GEF-Glo Bioluminescent Assay System368. 
Another option is to validate the GTPase system and detecting method 
using the NMR-based assay that was used to interrogate the Mant-GTP 
assay (reviewed in [426]). 
 
 
?????????????????????????????????????????????????????????????????????????
Recent data have shown that K-Ras-driven cancers are dependent on 
wild-type H- and N-Ras434. Thus, to determine whether the hit compounds 
had an efficacy in cells, we selected three cell lines that appear to be 
dependent on K-Ras signaling, since inhibition of the MAPK pathway 
effectively inhibits their cell proliferation. Two of the cell lines had 
activating KRAS point mutations; A549 (KRASG12S) and H460 (KRASQ61H) 
while the third, NCI-H292, did not carry KRAS mutations but was addicted 
to EGFR signaling through the Ras-MAPK pathway. We observed that 
three compounds displayed inhibitory effects on cell proliferation; QT-113 
selectively reduced cell growth of the wild-type KRAS cells, whereas QT-
43 and QT-46 inhibited the growth of all three cell lines, with the most 
prominent effect in cells possessing KRAS mutations  Figure 26). 
 
In order to determine whether the compounds that demonstrated dose-
dependent activity in the cell-based assays had a direct effect on cellular 
Ras protein, we examined their effect on nucleotide loading of Ras using 
serum starved EGF-stimulated HeLa cells. We found that a short 
incubation of QT-43 resulted in a moderate inhibition of EGF-induced GTP-
loading, while a prolonged incubation with both QT-43 and QT-113 
strongly reduced EGF-induced GTP-loading (Figure 27). Interestingly, we 
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noted that QT-43 not only effectively reduced Ras activation, there also 
seemed a baseline decrease total Ras. To rule out the possibility that the 
loss of Ras-GTP signal of prolonged QT-43 treatment was due to 
decreased input, presumably caused by decreased cell viability, we 
assessed protein expression and phosphorylation status using western 
blot analysis, investigating the effect of compound treatment on the Ras 
effector signaling pathways, MAPK and Akt (Figure 27). As before, HeLa 
cells were starved overnight and subsequently stimulated with EGF to 
induce Ras signaling. In line with the hypothesis that a decreased input 
caused the loss of signal, we did not observe any change in the two main 
downstream signaling pathways, MAPK and Akt, for compound QT-43. If 
any change was observed, it was an increase after 1 h of induction. A 
similar initial increase of signaling was observed for QT-113, with a 
substantial increase of pMEK both in baseline and EGF-stimulated sample. 
On the other hand, overnight treatment with QT-113 resulted in a  
 
 
Figure 27 Long-term compound treatment induces loss of Ras effector signaling through 
MAPK pathways. To investigate the effect of compound treatment on the Ras effector signaling 
pathways, HeLa cells were serum deprived for 18 h in the presence of 100 µM compound and 
subsequently stimulated with 200 ng/mL epidermal growth factor (EGF) to induce Ras signaling. 
No change was observed for compound QT-43 in the two main downstream signaling pathways of 
Ras, whereas compound QT-113 induced a reduction of pAkt and a near complete loss of MAPK 
signaling. 
?????????
??????????
?????? ? ??? ??????? ????
???? ? ? ? ? ?? ? ? ? ? ?
? ? ??? ??????? ???? ??????
?????????
?????????
??????????
??????????
??????????
 93
reduction of pAkt and a near complete loss of phosphorylation of the 
MAPK signal pathway proteins.  
 
Next we assessed the time point the effects of QT-113 treatment became 
apparent. Since biochemical inhibition of Ras cycling is expected to 
happen almost instantly, but the morphological changes that are 
depended on downstream signaling changes on might take some time, we 
focused on the first 8 h, including an overnight treatment as long-tem 
control. We analyzed the cell morphology by live-cell imaging as well as 
collected cell lysates for phospho-protein analysis. Within the first 30 min, 
we observed a strong phenotypic response such that the cells subjected 
to QT-113 showed enhanced membrane ruffling, suggesting a rapid 
response of some kind (Figure 28). This effect was restricted only to the 
serum starved, QT-113 treated cells, as the QT-113 treated cells in 
complete medium did not display any immediate effect. Subsequent 
western blot analysis of the two main Ras effector signaling pathways 
revealed no immediate inhibitory response. On the contrary, long-term 
treatment of QT-113 led to a reduction of pAkt as well as potent decrease 
of MAPK pathway phosphorylation, whereas the short-term treatment 
initially moderately increased phosphorylation levels. Analysis of the live-
cell imaging data revealed that the long-term treated samples had over 
the course of the experiment gradually built up a distinct phenotype. The 
majority of cells displayed extensive amount of vacuole formation close to 
the nucleus (Figure 28). Strikingly, this phenotypic effect was again only 
observed in the serum starved QT-113 treated cells, as cells treated with 
QT-133 in complete media or vehicle in starvation medium did not 
accumulate these vacuoles.  
 
Taken together, QT-113 does induce a potent biological effect in NCI-
H292 and HeLa cells, cells that carry RAS wild type genes. We did not 
observe growth inhibition using RAS mutant cell lines. Considering that 
the biochemical assay is designed with the intent to identify small 
molecule modulators of Ras GTPase cycling, GAP-insensitive mutant and 
cycling independent mutant cells will not be affected as much as RAS wild 
type cells. However, there are reasons to expect that the responses in 
NCI-H292 and HeLa cells are not linked to the effects seen in the 
biochemical Ras cycling assays. First, except for the fast, distinct  
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Figure 28 QT-113 treatment induces strong phenotypic response. Representative 20x phase-
contrast images of HeLa cells at different time points of the treatment. Cells were conditioned for 
6 h in complete medium (left column) or starvation medium (middle and right columns). 
Subsequently, cells were treated with 80 µM QT-113 (left and middle columns) or DMSO (right 
column). Within 15 min after compound addition (middle row), serum starved QT-113-treated cells 
exhibited ruffling of the membrane (middle panel), which was not observed in the complete 
medium counterpart or in either of the DMSO controls (left and right panel). Long-term exposure 
to QT-113 (>8 h) in starvation medium resulted in extensive amount of vacuole formation (last 
row, middle panel), while this phenotype was absent in both the complete medium counterpart 
and either of the DMSO controls (last row, left and right panel). Scale bar, 50 µm. 
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membrane ruffling (Figure 28), the overall response in cells occurred only 
after an extended incubation time with the compound, which is not 
consistent with biochemical inhibition of Ras cycling. Instead, the need for 
a long-term incubation argues that the reduction in Ras activation and 
downstream signaling comes as a result of the cells being severely 
affected by the long-term presence of the compound and, therefore, less 
responsive to external stimuli. In agreement with this conclusion we find, 
prior to the loss of response to EGF, that the compound-treated cells have 
accumulated large amounts of intracellular vacuoles. This distinct 
phenotype of extreme vacuolization has been associated with 
dysfunctional endocytosis and an unique form of non-apoptotic cell death 
in cell cultures called methuosis (reviewed in [435]), but is unclear 
whether this can occur under normal physiological conditions. Second, 
QT-113 is a compound flagged as a pan-assay interference compounds 
(PAINS)430. Its chemical structure is based on a fused tetra hydro-
quinoline backbone, which is a prime suspect for exhibiting false positive 
results in biochemical assays as well as complex effects in cell-based 
assays. Accordingly, QT-113 analogs deposited in PubChem that have 
been through thorough bioassay testing, appear as frequent positive 
results in diverse biochemical assays. One of these, Golgicide A436, is a 
compound affecting the Golgi apparatus. The limited biochemical and cell-
based data precludes us from knowing whether QT-113 would be a true 
false positive or whether it will have effects on the Golgi in cells, but it is 
likely to have complex and polypharmacological effects in cells. Therefore, 
if QT-113 should be followed up on, it should be explored using analogs 
that do not contain the PAINS-flagging elements. 
 
Despite the small number of compounds used in the proof-of-concept 
screen, we successfully used both the GTP hydrolysis assay as well as the 
nucleotide exchange assay to identify Ras cycle inhibitory molecules. 
Moreover, three of these compounds inhibited cell proliferation of Ras 
signaling dependent cell lines, of which one compound arguably showed 
to affect Ras GTP-loading. While none of the inhibitors exclusively 
identified with the GTP hydrolysis assay had any efficacy in the cell-based 
assays, the discovery of this unique set demonstrates the potential of this 
type of biochemical screening assays over the traditional assays that are 
designed to screen for inhibitors blocking a specific interaction of the Ras 
cycle. Given that this study was done with only a very small number of 
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compounds, it is likely that larger screens with greater chemical diversity 
will increase the probability of identifying cell active compounds. 
 ?
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6. Conclusions and future perspectives 
 
The advances in the field of molecular biology over the past fifty years 
have contributed to an increased understanding of the encoding role of 
genes and executive task of proteins, and that aberrant function is the 
molecular basis of human disease. Small GTPases and their regulators 
form highly integrated signaling networks that, under tight temporal and 
spatial control, regulate a myriad of different cellular pathways. It is not 
surprising that various members of the GTPase protein families are 
associated with multiple human diseases, like cancer, neurodegenerative 
diseases, and inflammatory disorders. However, to date, despite the 
rational, biology-driven drug development only very few small molecule 
modulators of GTPase activity exist. In this thesis, the aim was to identify 
new modulators by the development of new biochemical assays, 
specifically targeting the previously undrugged GTPase-regulatory 
proteins as their modulation is expected to result in specific inhibition of 
selected GTPase signaling pathways. 
 
Prior to these studies, RhoGAPs had not been successfully targeted in 
chemical biology or drug discovery. With the identification of MINC1 as a 
specific Rac1 - MgcRacGAP inhibitor, we showed in study I that RhoGAPs 
are both screenable and druggable small molecule targets. However, as 
MINC1 was discovered from a small molecule screen of over 360 000 
compounds and with optimization studies still unsuccessful, it shows that 
RhoGAPs are challenging small molecule targets. The reason why MINC1 
specifically inhibits Rac1-MgcRacGAP in vitro remains unknown. The 
recent observation that MgcRacGAP and Rac1 interact differently than 
other Rho GTPase and GAP pairs382, leaving a twice as large space 
between them, could explain the specificity and, more importantly, could 
assist in future in silico modeling to identify compounds with higher 
affinity and faster binding kinetics. We expect that analogs with increased 
potency will help to improve the understanding of the function of 
MgcRacGAP in both normal and malignant cellular processes. Further, to 
address the high potency in cellular systems in the immediate future, 
without the help of more potent analogs, it would be interesting to study 
MINC1 in GTPase FRET-based biosensor reporter systems. If functional 
changes will be observed, this could lead to next questions such as 
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whether local MgcRacGAP-mediated suppression of the Rac1-PAK pathway 
leads to the upregulation of RhoA within the division plane during 
cytokinesis. While both Rac and RhoA biosensor are available, the current 
binding kinetics of MINC1 are expected to be the limiting factor here. 
 
Until more potent analogs have been identified, MINC1 is a valuable tool 
to study the function of MgcRacGAP in cells, as we showed in study II. In 
this study we tested the hypothesis that had been put forward regarding 
the nuclear translocation of STAT3, which was supposedly facilitated by 
MgcRacGAP as both a mediator of STAT tyrosine phosphorylation and as a 
vital chaperone for nuclear translocation of STAT transcription factors. To 
explore the mechanism of MgcRacGAP controlling the activity of 
oncoprotein STAT3, we used MINC1 and siRNA-mediated gene silencing. 
Contradictory to published observations, we observed that inhibition of 
MgcRacGAP led to the transcriptional activation of STAT3. We found that 
the links between MgcRacGAP, Rac1 and STAT3 were highly complex; in 
the model system we used, MINC1-induced STAT3 transcriptional activity 
appeared to be due to increased STAT3 phosphorylation caused by a 
Rac1-PAR3-IL6-IL6R-JAK2 mediated autocrine/paracrine mechanism 
rather than a direct interaction between Rac1 and STAT3. However, direct 
interaction between Rac1 and STAT3 have shown to exist and, depending 
on cell type and status, even to co-exist with indirect interaction 
mechanisms420. Considering the role of STAT3 in cancer, it would be 
interesting to determine what factors regulate this apparent model and 
context dependency. Subsequently, disease specific models could be used 
for drug screening and eventually lead to improved drug therapies. 
 
Finally, in study III we presented a novel type of HTS-compatible 
biochemical assay that can be used to screen for both competitive as well 
as interfacial inhibitors for the Ras GTPase cycle. We utilized the dynamic 
behavior of GTPase signaling, designing an assay that can screen for 
small molecule compounds that bind to the Ras-GEF or Ras-GAP protein 
complex interface with high selectivity and locking the complex in one 
state. With a small proof-of-concept screen, we successfully identified 
compounds that affected H-Ras GTPase cycling in vitro. It remains to be 
studied whether the effects caused by QT-113 treatment in cells are 
direct or secondary, off-target effects. For instance, while QT-113 
treatment induced effects are restricted to RAS wild type cells, the effects 
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appear only after long-term incubation, which caused extensive amount 
of vacuole formation. Given that QT-113 is flagged as a possible pan-
assay interference compound, there is a likelihood that QT-113 interferes 
not only with the Ras cycle proteins, but with other proteins as well. 
Nevertheless, since this extreme vacuolization has been associated with 
dysfunctional endocytosis caused by aberrant signaling from H-Ras435, it 
would be interesting to study the effect of analog compounds that do not 
contain the substructural features that marked QT-113 as possible pan-
assay interference compound. Furthermore, it remains to be seen 
whether a screen using an increased number of compounds will allow for 
discoveries of interfacial inhibitors.  
 
When describing the literature about Ras family proteins and their 
regulators, it became apparent that drug-targeting efforts have mostly 
been disappointing. With recently discovered covalent inhibitors it has 
been shown that a small GTPase is directly drugable261,264, however their 
use is limited to the Ras proteins harboring the G12C mutation. 
Furthermore, while Ras-mimetic small molecule kinase inhibitor rigosertib 
has shown to be a potent inhibitor of tumor growth in several disease 
models287,288, in clinical setting only subgroups of patients have 
responded to treatment with rigosertib in a randomized trial293. It is not 
unlikely that this limited response is due to compensatory signaling 
cascades reducing the overall durability and potency of the treatment. 
With the emerging evidence that GAPs are oncogenic333, I anticipate that 
in the future more research will be focused on GAPs as it has been on 
GTPases and GEFs as well as downstream targets. The discovery of 
MINC1 demonstrates that RhoGAPs are druggable, and the assays and 
methodologies described in these studies could be used to design future 
studies in the largely unexplored field of targeting other small GTPase 
GAPs. 
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